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dividuals at risk for SD has become a major focus of the
cardiovascular community for a number of reasons,
including the opportunity to reduce SD events through
selective disqualiﬁcation from sports (7) and the pri-
mary prevention of SD with the implantable car-
dioverter-deﬁbrillator for some high-risk patients with
genetic heart diseases (8–14). In addition, those SDs
caused by underlying and unsuspected genetic orcongenital cardiovascular diseases that occur in young
trained athletes are a highly visible issue and have
become a concern in both the public arena and the
physician community (15–17).
Consequently, the desire to screen populations
theoretically at risk for cardiovascular disease to
reduce morbidity and mortality is understandable in
principle, and few would empirically argue against
the potential beneﬁt of this practice for some in-
dividuals. However, a debate has emerged regarding
whether the conditions responsible for these tragic
events can be detected effectively in populations of
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1480examination techniques, and speciﬁcally, there is debate
concerning which strategies are potentially the most
reliable to separate those individuals with disease from
those who are probably unaffected (15–29).
Most of this dialogue concerning SD prevention has
been limited to the screening of young populations of
competitive athletes, and the available data speciﬁcally
related to cardiovascular screening efﬁcacy (on which we
largely and unavoidably rely) overwhelmingly come from
such populations exclusively composed of trained ath-
letes. Periodically, this has become a polarized contro-
versy and public health debate, triggering a large and
growing body of literature, including clinical studies.
but notably also an array of recent editorials, opinion
pieces, proclamations, and reviews on both sides of the
question, often without the advantage of new primary
data (15–86). Most of these come from Italian in-
vestigators (n ¼ 19) and others (n¼14), who suggest that
the ECG is a reliable and economically feasible diagnostic
test, some prematurely pronouncing a paradigm shift
(49,78), whereas others appear contradictory (49,85);
other statements have come from an American Heart As-
sociation (AHA) science advisory (87) and a report from
the National Institutes of Health (23). Indeed, the issue of
preparticipation athlete screening for cardiovascular dis-
ease has become the subject of discussion in a number of
countries, including the United States,* Italy (4,18,31),
Israel (28,29,31,92,93), Germany (94), Sweden (95), the
United Kingdom (60,96), China (97), the Netherlands (98),
France (99), Norway (58), Denmark (5,100), Japan
(101,102), Switzerland (103), and Spain (104).
The present discussion deﬁnes cardiovascular
screening as an initiative intended to prospectively
identify or raise suspicion of previously unrecognized and
largely genetic or congenital cardiovascular diseases
known to cause sudden cardiac arrest and SD in young
people (3,105). This has become a highly visible and
vigorously debated topic, because the SD risk associated
with intense physical activity (in the setting of poten-
tially life-threatening but occult cardiovascular disease)
potentially could be modiﬁed by withdrawal from a
competitive athletic lifestyle (18) and could even bethe American Heart Association Council on Clinical Cardiology, Advocacy
Coordinating Committee, Council on Cardiovascular Disease in the Young,
Council on Cardiovascular Surgery and Anesthesia, Council on Epidemiology
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Council on Quality of Care and Outcomes Research, and American College of
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*References 3,15,20,22,24–26,59,62,64,88–91.preventable in high-risk patients by prophylactic treat-
ment interventions (e.g., implantable cardioverter-de-
ﬁbrillators) (8–14). The writing group believes that it has
achieved a comprehensive and balanced portrayal of the
highly visible but complex topic of population screening
for cardiovascular disease in young people.
NEW SCOPE OF THE DOCUMENT
Although reports on cardiovascular screening efﬁcacy
have predominantly involved populations of adolescents
and young adults participating in competitive athletics,
the context of the present discussion is intentionally (and
necessarily) much more expansive. Therefore, it is
underscored that the present report is not limited in scope
to universal mass screening for athlete populations but
importantly includes considerations for screening large,
young, and truly general populations (school-aged, 12–25
years old, of both sexes) with respect to relevant logis-
tical, ethical, legal, and societal issues (e.g., in the United
States or other countries or communities of various sizes,
in schools, or in regional or military populations). In the
United States, this potential screening population would
comprise z60 million young people nationally, including
as many as an estimated 10 million competitive athletes
(7.5 million interscholastic athletes and 500,000 inter-
collegiate athletes) (2,3,25,55,106).
The theoretical aspiration to screen the entire 12- to 25-
year-old population of the United States for cardiovas-
cular disease with ECGs would be an undertaking of
enormous magnitude, with massive resource demands, in
a population that may be at lower risk than one conﬁned
to athletes (107).
Indeed, systematic cardiovascular screening (beyond
periodic preventive health evaluation (5) in recreational
athletes and the general adolescent and young adult
populations) has not been recommended or pursued
previously, and such evaluations typically have been
reserved for patients with symptoms suspected to be of
cardiovascular origin. On the other hand, the fact that
screening has been limited to competitive athletes in the
past does not in principle itself justify the futureAssociation and the American College of Cardiology. J Am Coll Cardiol
2014;64:1479–514.
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1481exclusion of youthful nonathletes from screening for le-
thal cardiovascular disease. Therefore, it appears only
logical and fair that when relatively small athlete pop-
ulations are targeted for screening, at least some consid-
eration should be given to extending this screening to
nonathletes in the same jurisdiction and venue.
Finally, this discussion does not speciﬁcally address
the care provided to healthy individual subjects in an
ofﬁce practice. This represents a much different screening
alternative within the U.S. healthcare system, which is
restricted by the cost of such examinations generally not
reimbursed by insurance carriers (in the absence of sus-
pected disease).
SCREENING WITH THE ECG
The 12-lead ECG has been a widely used test to diagnose
cardiovascular disease, particularly acute myocardial
infarction, in clinic- and hospital-based practice for z70
years. Recently, the ECG has been promoted vigorously as
a screening test to detect or raise suspicion of predomi-
nantly genetic/congenital cardiac disease speciﬁcally in
large populations of young trained athletes, including
consideration for programs in entire countries.y
The present AHA statement represents a detailed
critique of the available evidence both for and against the
ECG as a screening test to systematically detect cardio-
vascular disease in large general populations of young
people (including national initiatives), as well as in more
limited screening venues. The document also evaluates
the relative merits of the ECG compared with standard
history-taking and physical examination for cardiovas-
cular screening.
This question of screening ECGs in the young has
become increasingly relevant, largely by virtue of the
reduced mortality rates in competitive athletes reported
speciﬁcally from the Veneto region of northeastern Italy,
which the Italian investigators have attributed to routine
screening ECGs (4,15). Furthermore, in 2005, the Euro-
pean Society of Cardiology (ESC) formally recommended
and has strongly promoted national screening initiatives
with ECGs (limited to athletes) to other countries in
Europe and the United States (5). Notably, the discussion
of such mass screening initiatives and models has come to
be regarded as complex by virtue of 1) the low prevalence
of cardiovascular diseases responsible for SD in the young
population, 2) the low risk of SD among those with these
diseases, 3) the large sizes of the populations proposed for
screening, and 4) the imperfection of the 12-lead ECG as a
diagnostic test in this venue.yReferences 4,5,16,18,19,21,28,31,32,36,45,49,57,62,78.Echocardiography, although not a primary subject of
the present discussion, does harbor advantages for clinical
diagnosis of certain conditions, such as hypertrophic
cardiomyopathy (HCM) (108). However, neither echocar-
diography nor cardiovascular magnetic resonance has
been considered seriously as a primary cardiac imaging
strategy or modality for large-scale universal prepar-
ticipation screening because of impracticality, cost, and
interobserver variability (109). Echocardiograms, never-
theless, are an important part of second-tier examinations
that frequently occur when screening ECGs or other clin-
ical ﬁndings are judged abnormal (2,3,17,55,109).
Both AHA (3) and ESC (5) consensus panels have
agreed previously that screening to detect cardiovascular
abnormalities in asymptomatic young competitive ath-
letes is justiﬁable in principle on ethical, legal, and
medical grounds. Reliable exclusion of cardiovascular
disease by such screening may provide a large measure of
reassurance to this speciﬁc population of young people
and their families. However, the U.S. and AHA position
against national mandatory screening ECGs of athletes in
the United States has periodically been the source of
strong reaction and criticism from some investigators
(16,27,39,43,62,77,110). In addition, the question has
arisen of whether such a mass screening program with
ECGs is ethically defensible if conﬁned to only 1 segment
of the population when others may also be at risk.
BACKGROUND OF U.S. SCREENING PROGRAMS
Although rare, SDs in young people are nonetheless tragic,
devastating events. Consequently, the detection of silent
predominantly genetic/congenital cardiovascular condi-
tions responsible for SD is an objective consistent with a
benevolent and compassionate society. In the past, partic-
ipants in competitive sports have been preferentially tar-
geted for such screening programs, apparently because of
their unique, physically active lifestyle (4–7,107). Indeed,
in the United States, there is a long-standing (>50
years) customary practice of systematic preparticipation
screening required for participation in most organized
youthandsanctionedhighschool, college, andprofessional
sports, principally by use of history-taking and physical
examination (20,22,111). Of note, similar mass examination
initiatives have not been advocated for the much larger
general population of children, adolescents, and young
adults who may not participate in organized sports activ-
ities, and therefore, there are virtually no data from such
cohorts regarding the detection of cardiovascular disease.
In 1996 and again in 2007, the AHA provided consensus
recommendations for such evaluations speciﬁcally in
competitive athletes (3,105,112), deﬁned as those who
participate in an organized team or individual sport that
requires regular competition against others as a central
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achievement, and requires some form of systematic (and
usually intense) training (7,113). Twelve elements (now 14)
of the personal and family history and physical examina-
tion were recommended as part of a comprehensive med-
ical questionnaire to be used as a guide to examiners
conducting preparticipation examinations (Table 1),
although the precise penetrance of these guidelines into
various levels of clinical practice is uncertain (114). Other
societies have also formulated useful guidelines for the
preparticipation history and physical examination (115).
In the United States, the preparticipation screening
process has lacked a measure of standardization,
including in the selection of examiners, who have tradi-
tionally included professionals from a variety of disci-
plines with different levels of training and expertise
(e.g., physicians, nurse practitioners, physician assis-
tants, and chiropractors in a minority of the states), often
participating as volunteers (3,20,22). Physicians respon-
sible for screening are most often from the primary care
and sports medicine disciplines but may also include a
variety of other medical or surgical specialists (but rarely
with speciﬁc cardiovascular training).
However, more recently, cardiologists have become
more involved with the care of athletes, mostly at the elite
level. This practice contrasts sharply with the Italianmodel
(116), in which screening is performed by a cadre of
specially trained primary care–sports medicine physiciansTABLE 1 The 14-Element AHA Recommendations for Prepartici
Medical history*
Personal history
1. Chest pain/discomfort/tightness/pressure related to exertion
2. Unexplained syncope/near-syncope†
3. Excessive and unexplained dyspnea/fatigue or palpitations, associated with e
4. Prior recognition of a heart murmur
5. Elevated systemic blood pressure
6. Prior restriction from participation in sports
7. Prior testing for the heart, ordered by a physician
Family history
8. Premature death (sudden and unexpected, or otherwise) before 50 y of age
9. Disability from heart disease in close relative <50 y of age
10. Hypertrophic or dilated cardiomyopathy, long-QT syndrome, or other ion cha
knowledge of genetic cardiac conditions in family members
Physical examination
11. Heart murmur‡
12. Femoral pulses to exclude aortic coarctation
13. Physical stigmata of Marfan syndrome
14. Brachial artery blood pressure (sitting position)§
AHA indicates American Heart Association. *Parental veriﬁcation is recommended for high scho
of particular concern when occurring during or after physical exertion. ‡Refers to heart mu
performed with the patient in both the supine and standing positions (or with Valsalva maneuv
§Preferably taken in both arms. Modiﬁed with permission from Maron et al. (3). Copyright ªdedicated to examining all athletes in the national pro-
gram, as well as being responsible for disqualiﬁcation de-
cisions (4,5,18).
CARDIOVASCULAR CAUSES AND
EPIDEMIOLOGY OF SD IN THE YOUNG
The causes of SD in the age group addressed here have
been well documented, although based primarily on
studies in the competitive athlete population, often in
the form of large registries and forensic databases
(1,2,4–6,117–122). There is no evidence at present that the
speciﬁc causes of SD differ signiﬁcantly in nonathletes.
The causes of SD in trained U.S. athletes 12 to 35 years
of age have been reported in a consistent fashion since
1980 (1,2,6,117,120–123). A heterogeneous variety of
mostly congenital/genetic diseases (z20) are responsible
for these events, with HCM (1–3,6,7,117,122,124–125a)
being the single most common cause of SD, constituting
approximately one third of cases (1,2,6,117,119,125).
Congenital coronary anomalies (most commonly those of
wrong sinus origin) are responsible for 15% to 20%, with
several other diseases each being responsible for z5% or
less, including myocarditis, valvular heart disease (e.g.,
mitral valve prolapse, aortic stenosis), dilated cardiomy-
opathy, ruptured aortic aneurysm, premature athero-
sclerotic coronary artery disease, and arrhythmogenic
right ventricular cardiomyopathy/dysplasia (ARVC/D), aspation Cardiovascular Screening of Competitive Athletes
xercise
attributable to heart disease in $1 relative
nnelopathies, Marfan syndrome, or clinically signiﬁcant arrhythmias; speciﬁc
ol and middle school athletes. †Judged not to be of neurocardiogenic (vasovagal) origin;
rmurs judged likely to be organic and unlikely to be innocent; auscultation should be
er), speciﬁcally to identify murmurs of dynamic left ventricular outﬂow tract obstruction.
2007, American Heart Association, Inc.
zReferences 2,25,54,99,100,120,125,127,129,130.
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1483well as a variety of other congenital heart malformations.
A small proportion of these deaths (2%–3%) are not
associated with structural cardiac abnormalities at au-
topsy, including Wolff-Parkinson-White preexcitation,
ion channelopathies, and sickle cell trait. Other causes not
directly related to preexisting cardiovascular disease
include bronchial asthma, ruptured cerebral aneurysm,
use of performance-enhancing or other drugs and sub-
stances, heat stroke, and pulmonary embolus.
The mechanism of death in the vast majority of these
events is a ventricular tachyarrhythmia, with the major
exception being Marfan syndrome and related disorders
associated with aortic dilatation, in which SD usually oc-
curs because of aortic dissection/rupture.
SDs occur in a wide variety of sports, most commonly
football and basketball in the United States and soccer in
European countries. There is considerable gender bias
in these events, with a male to female ratio of z9:1
at all levels of competition (1,2,7,37,117,125–129), and
with occurrence reported in a number of racial/ethnic
groups, including whites, blacks, Asians and Hispanics
(1,2,6,117,120–122,125–127). Similarly, SD risk was 30-fold
less in females than males during recreational sports in a
national study from France (128).
Notably, the pathology of SD reported in trained
athletes from the Veneto region of Italy (4,18) differs
substantially from the experience elsewhere
(1,2,6,117,119,125). Paradoxically, ARVC/D (very uncom-
mon in the U.S. data) is uniquely positioned as the most
frequent and important single cause of these SDs in
Veneto, possibly because of a unique genetic substrate
(4,14,31,130,131). Atherosclerotic coronary artery disease
is also relatively common in Veneto, whereas HCM (the
most common cause of SD in U.S. registries) (1,2,6,117,122)
is a rare cause of these deaths in the Italian (Veneto)
experience.
Long-standing screening efforts in athletes in the
United States, Italy, and Israel have been predicated on
the rationale that individuals engaged in competitive
sports represent a special subset of the general population
who are at signiﬁcantly higher risk for SD than individuals
of similar age who are not involved in such athletic ac-
tivities and lifestyle (6,26,31,107,117). Such an assertion
has been used to justify screening initiatives that target
only competitive athletes. However, although the prem-
ise that SD caused by underlying (and unsuspected) car-
diovascular disease is more common with engagement
in intense physical exertion is intuitive and supported by
some data (6,107), this issue remains incompletely
resolved.
Comparative data and evidence supporting this pre-
sumption that athletes are at greater risk than nonathletes
comes largely from Veneto, where competitive athletes
had a relative risk for SD of 2.5- to 4.5-fold compared withnoncompetitive recreational sports participants or non-
athletes of similar age (4,107). Also, the National Colle-
giate Athletic Association (NCAA) study by Harmon et al.
(126) inferred greater risk for college athletes in particular
sports but did not include a direct comparison to non-
athletes and was devoid of forensic data to conﬁrm the
true cardiovascular cause of death.
Therefore, we wish to underscore that SDs attributable
to unsuspected genetic/congenital cardiovascular dis-
eases are not limited or largely conﬁned to trained ath-
letes. Rather, it is likely that the absolute number of these
SD events is higher in the larger population of young
people who have not elected to engage in organized
sports and may not have a particularly vigorous athletic
lifestyle. Indeed, an estimated 10% to 15% of 12- to
25-year-olds participate in organized sports competition,
and it is very likely that the majority of those who
die suddenly of HCM or other cardiovascular diseases do
so unassociated with competitive athletic lifestyles (106).
SDs in nonathletes do not receive the same intense
media exposure and scrutiny as athletes, which probably
accounts for the misperception that such events are less
common among them. Indeed, a large prospective,
epidemiological, general population study from France
showed SDs in young noncompetitive or recreational
athletes were >15-fold more frequent than in competitive
athletes; only 6% of sports-related cardiac arrests
occurred in competitive situations (10 SDs per million per
year), whereas >90% took place in recreational settings
(99).
MAGNITUDE OF THE PROBLEM
Young Competitive Athletes
Most data describing the magnitude of cardiovascular SDs
in young people come from healthy competitive athlete
populations characterized by different levels of training
and achievement, as well as various ethnic origins. Based
on the preponderance of available evidence from both
absolute death rates and incidence ﬁgures, assembled
largely in high school and college-aged competitive ath-
letes, SD events attributable to underlying cardiovascular
disease can be considered a relatively low event rate
phenomenon.z
Although incidence rates are important in assessing
relative risk in a given population, absolute death rates
are also useful in quantifying the overall magnitude of a
public health problem. For example, absolute annual
death rates have been accessed from the long-standing
U.S. National Registry of Sudden Death in Athletes
(2,6,117), which has tabulated >2,500 events in young
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recording about 75 cardiovascular deaths in a given year.
All-cause mortality in athletes, including from blunt
trauma, commotio cordis, drugs, and heat stroke, has
averaged z115 deaths per year (2). These data are
consistent with estimates from other countries. For
example, in Denmark, with a population of 5.6 million,
z2 such cardiovascular deaths are reported annually,
equivalent to 110 deaths per year if extrapolated to the
U.S. population (100).
It is important to place into proper perspective these
absolute numbers of SDs, because the frequency of
these events is a very important variable in the screening
debate. Cardiovascular deaths in young athletes in the
United States each year are much less frequent than
virtually all other causes of death in the same age group
(25,125) (Figure). Motor vehicle accidents are the leading
cause of death in the young, z2,500-fold more common
than events during sports, and many are linked to alcohol
consumption or cellular phone distraction and therefore
are largely preventable (139). For example, in an analysis
of NCAA athletes, 3-fold more deaths were caused by ac-
cidents than by cardiovascular disease over the same time
period (126). Furthermore, SDs attributable to cardiovas-
cular disease in young athletes in the United States occur
at an annual rate similar to lightning strike fatalities
(Figure). In another study (125), conﬁrmed cardiovascular0 100
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CV indicates cardiovascular; MN, Minnesota; and NCAA, National Collegiate AthSDs occurred with a frequency similar to those largely
preventable deaths that were attributable to suicide or
drug use in NCAA athletes.
Mortality incidence data (expressed as athlete-partici-
pation years or person-years) is a crucial element in the
dialogue over ECGs and screening, supporting the asser-
tion that cardiovascular deaths related to competitive
athletic activities are essentially rare events. A recent 26-
year survey (1986–2011) of Minnesota high school athletes
reported an incidence of cardiovascular-related deaths of
1 in 150,000 per academic year (0.7/100,000 person-years)
(127). These ﬁgures are consistent with data from U.S.
high school and collegiate athletes (1:200,000, 0.53/
100,000 person-years) (120), the U.S. National Registry of
Sudden Death in Athletes (1:100,000, 0.61/100,000
person-years) (2), a 12-year survey of Minnesota high
school athletes based on obligatory insurance claims
(1:200,000, 0.5/100,000 person-years) (129), young
competitive athletes in Minnesota from 1993 to 2004
(1:110,000, 0.93/100,000 person-years) (130), NCAA ath-
letes with forensic data (1:83,000, 1.2/100,000 person-
years) (125), and athletes in Veneto (1:110,000, 0.87/
100,000 person-years; 1993–2004) (130), as well as young
(not necessarily athletic) residents of Olmsted County,
Minnesota (1.3/100,000 person-years) (140) or Ontario,
Canada (1.0/100,000 per person-years (140a), and young
Danish athletes (1.2/100,000 person-years) (100).0 2000 3000 4000 5000 6000 7000 8000 9000 10000 11000 12000
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1485Mortality rates in college (NCAA) athletes appear to
exceed somewhat those in high school student-athletes,
possibly because of longer exposure to training. However,
mortality rates in college student-athletes are signiﬁ-
cantly lower when studies include postmortem data that
establish cardiovascular diagnoses (125) than when the
precise cause of SD is unknown (1.1/100,000 versus 2.3/
100,000 person-years) (126). Finally, there is no evidence
that SDs due to genetic/congenital heart disease in young
populations (athletes or nonathletes) have increased in
frequency over time.
The reported incidence of 4.3 per 100,000 person-years
in Veneto at the time screening ECGs were initiated in
1982 (and presumably largely attributable to ARVC/D) is
by far the highest reported from any population (4). This
incidence is almost 2-fold greater than the rate of athlete
deaths in Israel (2.6/100,000 person-years), evident both
before and after enactment of mandatory screening ECGs
legislation (28). A rate comparable to that in Israel has
only been reported in U.S. college (NCAA) athletes by
Harmon et al. (126) based on 9 deaths per year among
400,000 participants but without autopsy conﬁrmation of
the causes of cardiovascular death (141).
A more recent study in NCAA student-athletes with a
more expansive time window and forensic (postmortem)
conﬁrmation of the causes of death reported a much lower
cardiovascular SD rate of 4 deaths per year, which suggests
that the cardiovascular SD rate in NCAA athletes had been
overestimated previously by >100% (125). The 2 studies in
the literature that reported the highest cardiovascular SD
rate in athletes (>2/100,000 person-years; i.e., from Israel
(28) and fromHarmon et al. (126) in NCAA athletes) failed to
document the diseases or precise causes of SDs (because of
the absence of autopsy data) (141), and therefore, it is not
possible to know precisely which (or how many) deaths
were actually attributable to cardiovascular diseases or
potentially identiﬁable by screening ECGs.
Limitations
Because mandatory reporting systems for SDs in young
people (including athletes) do not exist in the United
States or most other countries, analyses of event fre-
quency (the numerator) are usually highly dependent on
accounts in the public record, from the Internet, or from
personal communications for the identiﬁcation of events
that provide important epidemiological and clinical
information,x and this could result in an underestimation
of the true mortality rate. In addition, in retrospective
population surveys, it is difﬁcult to establish precisely the
size of the at-risk populations (the denominator). There-
fore, the prevalence and incidence ﬁgures relied on inxReferences 1,2,6,117,122,123,125,127,129.these heterogeneous populations can only be considered
reasonable estimates of SD frequency.
Each of the population studies that calculates mortality
rates and incidence is imperfect; such studies are
encumbered by certain not unexpected limitations and
design ﬂaws for determining the absolute number of
events (numerator) and the at-risk population (denomi-
nator), not the least of which are the different method-
ologies used for data acquisition in various countries. All
of this justiﬁes the scrutiny provided here. Therefore, the
writing group recognizes the potential value, but difﬁcult
task, of establishing additional registries that reliably
document the numerator (SD events) and the denomina-
tor (at-risk population) in young people (athletes and
nonathletes alike).
The writing group also acknowledges that the public
health issue of SD in young people cannot be viewed
solely from the perspective of its relatively low incidence.
By emphasizing the low SD incidence, we do not wish to
suppress interest in secondary prevention treatment
strategies that could further reduce the occurrence of
these tragic events, i.e., enhanced early resuscitation/
deﬁbrillation programs and wider dissemination of auto-
mated external deﬁbrillators proven to be effective in the
management of sudden cardiac arrest on the athletic ﬁeld
(24,64,142–145).
The unexpected and counterintuitive deaths of young
and apparently healthy people, potentially with decades
of productive life ahead of them, deserve our full atten-
tion. The infrequency of these events in no way mitigates
their importance or impact on families and the commu-
nity. However, it should also be underscored that the
unexpected nature of these tragedies on the athletic ﬁeld
magniﬁes the public perception of their incidence,
particularly when a highly visible athlete is involved.
Notably, the visibility and intense media focus on SDs
speciﬁcally in athletes may have created the erroneous
impression that these tragic events are far more common
than their actual frequency, or even the misconception
that such deaths are virtually conﬁned to athletes. Such
misperceptions have legitimized screening initiatives
limited to athletes, in turn perhaps diverting resources
from themany other important public health issues for this
age group, including but not conﬁned to preventable ac-
cidents or other causes such as drug abuse, childhood
obesity, and suicide intervention (Figure). Indeed, in a
10-year study of U.S. college athletes, Maron et al. (125)
found suicide and drugs to be as frequently responsible for
SD as cardiovascular disease. Although SD caused
by cardiovascular disease in young people engaged in
competitive sports is a signiﬁcant public health concern,
its relatively low incidence could limit the overall
priority for universal primary prevention screening
(Figure).
Maron et al. J A C C V O L . 6 4 , N O . 1 4 , 2 0 1 4
Assessment of the 12-Lead ECG as a Screening Test O C T O B E R 7 , 2 0 1 4 : 1 4 7 9 – 5 1 4
1486Public Access Competitive Sports
There have been multiple studies tabulating SD event
rates in long-distance running (including the marathon),
as well as the triathlon (144–147). Unlike those in sanc-
tioned high school and college sports, these athletes are
usually older adults who participate of their own volition
and are most likely to have unsuspected coronary artery
disease as the cause of SD, although occasionally HCM or
congenital coronary anomalies are responsible (144–147).
Mandatory or mass screening in this athlete population is
impractical given the thousands of participants annually,
with disqualiﬁcation for detected cardiovascular disease
an unenforceable policy. By convention, participation in
such sports has been the prerogative and responsibility of
the adult athlete, who accepts the inherent risks of
serious injury or death during athletic competition.
SD/cardiac arrest event rates are reported to bez0.5 per
100,000 marathon competitors, with fatalities in recent
events less common because of the greater availability of
automated external deﬁbrillators on the race course (145).
In triathlon competition (which includes distance running
up to the marathon distance), 1 study reported a higher
SD rate of 1.5 per 100,000 participants, with 90% of the
events occurring during the swimming segment (144).Professional Athletes
The relatively small number of participants in professional
sports (probably z5,000 in the United States, including
major and minor league competition) are unique
competitive athletes in several respects. Professional
athletes are primarily of adult age (>21 years of age), well
compensated for their services with employment con-
tracts, and part of organizations with ﬁnancial resources
for screening beyond those of high schools and college
athletic departments (111). Predraft diagnostic testing with
ECGs occurs in z90% of the 122 major professional sports
teams operating in North America, but routine echocar-
diography is uncommon (only 15% of teams) (111). The
most extensive routine screening is conducted by the
National Basketball Association, including history-taking
and physical examination and the performance of an ECG,
echocardiography, and stress testing (111). To the best of
our knowledge, there are no data documenting the fre-
quency with which potentially lethal cardiovascular ab-
normalities are identiﬁed in professional athletes through
systematic screening. However, a cluster of 3 highly
visible SD events caused by HCM occurred in professional
football, basketball, and hockey during a brief 4-month
period (in 2005) in the United States (148).
Olympic athletes are essentially professionals in many
countries. We are unaware of any athlete who has died
suddenly of cardiovascular disease during Olympic or
world championship competition, and the prevalence ofpotentially lethal cardiovascular disease at this elite level
of competition is undoubtedly low. Nevertheless, the In-
ternational Olympic Committee and those of several Eu-
ropean countries have recommended or adopted testing
with ECGs for Olympic candidates (98,103,149), as has
FIFA (Fédération Internationale de Football Association),
the international governing body of soccer (150). Routine
screening with ECGs is not required for U.S. Olympic team
members.
SCREENING EXPERIENCES IN
GENERAL POPULATIONS OF NONATHLETES
The few available data estimating the incidence or prev-
alence of SD in young people in large general populations
(not conﬁned to athletes) suggest that mortality rates
generally exceed those reported for competitive athletes.
Speciﬁcally, out-of-hospital cardiac arrest incidence has
been reported variously as 6.4 per 100,000 person-years
(151) and 3.2 per 100,000 person-years (152) in the pedi-
atric population and 2.3 per 100,000 person-years in a
pediatric and young adult population (153), and the SD
rate in the general youthful population of Denmark is 3.76
per 100,000 person-years (100). The prospective Oregon
Sudden Unexpected Death Study (154) reported an inci-
dence of 1.7 per 100,000 person-years among children and
adolescents aged 10 to 17 years over 3 years, when
extrapolated to the overall U.S. population is equivalent
to z500 deaths per year, a number signiﬁcantly higher
than that reported from the U.S. National Registry of
Sudden Death in Athletes (2).
Notably, the nonathletes reported from Veneto had the
lowest cardiovascular mortality rate reported in a general
population (0.79 per 100,000 person-years [4]), but
similar to rates in trained athletes in U.S. high schools and
colleges (120), the U.S. National Registry of Sudden Death
in Athletes (2), and data from both Minnesota and Veneto
during the 11-year time-frame from 1993 to 2004 (130), as
well as data from Olmsted County, MN, residents (140). In
Denmark there was no difference in the incidence of
sudden death between noncompetitive and competitive
athletes, both of which were signiﬁcantly lower than in
the general population (154a).
Military Personnel
Because engagement in the military is a highly physical
enterprise, SD rates attributable to unsuspected cardio-
vascular disease are often compared with those in trained
athletes (155,156). Sudden nontraumatic cardiac death
among active duty military generally occurs at higher
rates than in trained athletes, probably because intensive,
prolonged exertion is performed under extreme envi-
ronmental conditions, often by previously untrained in-
dividuals; rates are 6.7 per 100,000 person-years in men
kReferences 1–3,5,72,84,85,87,95,172,173.
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1487(1.4/100,000 person-years in women), with 40% of these
events temporally related to exertion according to data
from a comprehensive U.S. Department of Defense regis-
try (156). The most common cause of SD among active
duty military personnel <35 years of age is premature
atherosclerotic coronary artery disease (23% of cases),
followed by HCM (12% of cases), but SD is unexplained in
a large proportion of cases (40%).
Screening for cardiovascular disease (and other condi-
tions) is usually mandatory for military recruits. For
example, each applicant to the U.S. military completes a
screening questionnaire and undergoes a physical exam-
ination. ECGs are performed only selectively as guided by
history, symptoms, or physical ﬁndings (157). However,
ECGs are a routine part of medical screening in candidates
for aviation duty and in soldiers >40 years old (158). From
Italy, Nistri et al. (159) reported on a military screening
program from 1992 to 1996 that included history-taking,
physical examination, and routine performance of a 12-
lead ECG. Among 34,910 conscripts >17 years old, 8% had
abnormalities that prompted further evaluation. Of those
studied with echocardiography because of an abnormal
ECG, 0.7% (n ¼ 19) had a new diagnosis of HCM.
Sudden Infant Death Syndrome
The relation between sudden infant death syndrome
(SIDS) and long-QT syndrome (LQTS) was ﬁrst proposed by
Maron et al. (160). Schwartz et al. instituted ambitious
screening studies with 12-lead ECGs of >30,000 healthy
neonates in the ﬁrst week of life, who were followed up for
1 year, (161) and subsequently a study of almost 45,000
neonates at 15 to 25 days of life (162). A prolonged QT in-
terval was strongly associated with SIDS, and LQTS mu-
tations in the sodium channel (163–165) were found most
commonly in those SIDS infants with longer corrected QT
interval values (166). Therefore, neonatal screening ECGs
have been suggested as a means of identifying some cases
of LQTS as a cause of SIDS, but this strategy has been
controversial (167). It appears likely that only a small mi-
nority of SIDS cases can be linked to LQTS (164,165).
Although the available data suggest that neonatal LQTS
can be detected by screening (162), these studies have
failed to demonstrate that lives are saved by this strategy.
School-Aged Children
Relatively few screening programs have focused on the
1- to 12-year-old age group. The 1973 Japanese School
Health Law mandated cardiovascular screening with
modiﬁed ECG and history/physical examination for
thousands of children in the ﬁrst, seventh, and tenth
grades (101,102,168). However, few relevant disease-
related data have emerged from this initiative given that a
variety of generally minor cardiovascular abnormalities orarrhythmias without underlying organic heart disease
were identiﬁed in only 2% to 3% of children.
OTHER SCREENING INITIATIVES
Sickle cell trait (HgS) is present in 8% of blacks (and
0.08% of nonblacks), occasionally in association with
exercise-related cardiovascular collapse and SD, and
often in association with rhabdomyolysis in military re-
cruits and competitive athletes (predominantly college
football players) (138). Unlike SD attributable to underly-
ing cardiovascular disease and ventricular tachyar-
rhythmia, sickle cell trait–related collapse probably
results from a more gradual deterioration and cascade of
events, with intravascular sickling leading to vascular
occlusion, endothelial damage, and impaired blood ﬂow
to muscles, which can promote ischemic rhabdomyolysis
and disseminated intravascular coagulation (138,169).
In 2010, the NCAA mandated sickle cell trait screening
(with solubility testing) for all student-athletes in Divi-
sion I sports (170). This program was created as part of a
legal settlement with Rice University and the NCAA ﬁled
by the family of a college football player who died of ex-
ertional sickling with rhabdomyolysis at age 19 years
(170). Also, all blacks and others are tested routinely for
sickle cell trait at birth since 1987, following a recom-
mendation from the National Institutes of Health (171).
Concerns have been raised regarding the NCAA
screening program, including potential infringement on
individual privacy and liberty and the effects of such
testing on self-image and employability in professional
sports (170). As yet, there are no data that support sickle
cell trait testing as lifesaving, although awareness has
been raised regarding this potential problem in sports.
Although affected athletes are not disqualiﬁed from
sports, modiﬁed conditioning methods have been widely
used by college athletic programs to prevent sickle cell
trait events. In selected cases, athletes with sickle cell
trait have decided not to participate in competition at
high-altitude locations (138).
SCREENING MEDICAL HISTORY
AND PHYSICAL EXAMINATION
There is general agreement that conducting a compre-
hensive screening personal and family history and phys-
ical examination is usefulk; however, data supporting the
efﬁcacy of such a screening strategy alone are limited.
Available evidence shows that the personal/family his-
tory, as part of the preparticipation examination, is rela-
tively insensitive in identifying (or raising suspicion of)
cardiovascular abnormalities, including many of the
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false-negatives) (82,173). In 1 retrospective study of
competitive athletes who died suddenly after screening
with standard history and physical examination, <5% had
a conﬁrmed cardiovascular diagnosis during life (174).
The relative weakness of the history and physical
examination for screening can also be traced to other
factors. For example, with ion channelopathies and Wolff-
Parkinson-White syndrome, only the ECG potentially de-
ﬁnes the clinical phenotype, and the physical examination
is unremarkable. For many of the structural cardiac dis-
eases responsible for SD, symptoms, family history of heart
disease, and loud pathological heart murmurs are infre-
quent ﬁndings. One potential exception is HCM, in which a
systolic heart murmur (indicative of left ventricular
outﬂow obstruction) should be audible at rest in 25% of
individuals and in an additional 50% with performance of
the Valsalva maneuver or in the standing position (3,175).
Also, at-risk individuals may fail to disclose potentially
important symptoms such as syncope or chest pain (173).
Nevertheless, it should be underscored that an
important proportion of adolescents and young adults at
risk for SD with primary structural or electrophysiological
cardiac abnormalities may have warning signs and
symptoms (e.g., syncope) or a positive history of heart
disease potentially detectable by careful evaluation,
although nonetheless misinterpreted or disregarded by
medical providers (72,95,173). Furthermore, all exam-
iners, particularly those in primary care, are often faced
with difﬁcult decisions of whether potentially important
ﬁndings from the history and physical examination such
as heart murmurs (which are often functional in nature)
or symptoms such as chest pain (common in adolescents
and often difﬁcult to interpret) should receive sufﬁcient
weight to warrant an expensive cardiovascular referral
and evaluation (173). This often becomes a dilemma for
examiners, given that the vast majority of such in-
dividuals are likely to be unaffected, and the ﬁnding
will be benign. Although the 12-lead ECG can be re-
garded as more sensitive than the history and physical
(91,98,104,172), it is nevertheless associated with
reduced speciﬁcity because of false-positive results
(17,24,25,55,64,65,88,91). However, the acknowledged in-
sensitivity of the history and physical examination
screening cannot be considered a major justiﬁcation for
mass screening of general populations with ECGs.
Unfortunately, there is apparently a considerable
lack of awareness (and compliance) regarding the use
of history and physical examination questionnaires
to guide the preparticipation screening examination
(3,20,22,114,176,177). Indeed, certain standardized and
comprehensive questionnaire forms developed specif-
ically to assist primary healthcare providers in performing
these examinations have been grossly underused,speciﬁcally the AHA recommendations (3,105,112,114) and
the Preparticipation Physical Evaluation monograph/
form, which is the work of several different societies
(115,176).
It has been an important aspiration to enhance the
quality of the history-taking and physical examination
process (including the expertise of examiners) in accor-
dance with the speciﬁc 14-point recommendations of the
AHA (3,105) (Table 1), given that many states have exami-
nation questionnaires judged inadequate to reliably raise
suspicion of cardiovascular disease in high school student-
athletes (20,22). In 1998, Glover and Maron (22) critiqued
the completeness of the screening questionnaire process in
each state for high school student-athletes, measuring
compliancewith the recommendedAHA items that serve as
a guide to examiners. Nine years later in 2007, reanalysis
showed the questionnaires to be more comprehensive by a
factor of 43%, which suggests that the 1998 data probably
triggered revision in several states (20). Whether this
improvement in the questionnaires resulted in greater
numbers of affected individuals being identiﬁed is un-
known, although likely. An analysis of questionnaires used
by 879 NCAA member institutions (177) proved similar to
the data for U.S. high schools in 1998 (20) with respect to
the number of AHA items used (20,22).
In addition, in the United States, a minority of states
allow nonphysician examiners with little cardiovascular
training to perform preparticipation examination on high
school athletes (20,22). Therefore, future efforts should
focus at a minimum on improved dissemination and
enhanced practitioner awareness, compliance with (and
implementation of) the AHA screening recommendations
in the practicing community, and systematic recruitment
of physician examiners, as well as the possible creation of
an accreditation process.
Consideration should also be given to the standardi-
zation of preparticipation examinations and question-
naire forms (as guides to examiners) within each state or
possibly nationally in collaboration with organizations
such as the National Federation of State High School As-
sociations and the NCAA. In this regard, contrary to the
myth that the customary history and physical examina-
tions are of no value or merit, HCM investigators have
reported that a number of new HCM diagnoses and re-
ferrals do in fact come directly from preparticipation
history and physical examinations in athletes (178).
ASSESSMENT OF THE 12-LEAD ECG AS A
POPULATION SCREENING TEST
General Considerations
Although screening ECGs in young people have been used
for the purpose of promoting cardiovascular safety,
including but not limited to participation in competitive
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ulations with the 12-lead ECG remain controversial.{
Notably, mass screening with ECGs as discussed here
represents the interfacing of complex cardiovascular dis-
eases with an imperfect screening test, and the recognition
that no screening strategy or program can be expected to
reliably detect all affected individuals or eliminate SD.
The ECG has the capability of raising suspicion for or
identifying certain genetic cardiovascular diseases as true-
positive results, including ion channelopathies (184) and
HCM (18,185). However, screening ECGs for genetic or
congenital cardiovascular disorders in young people has
important potential and inherent scientiﬁc limitations,#
particularly in the relationship between pattern analysis of
the 12-lead ECG and the heterogeneous structural forms of
heart disease that are known to cause SD in the young. The
usefulness and consequences of routine screening ECGs
depend on the purpose of acquisition of the ECGs, technical
quality of the recording, selection of the study population,
distinguishing factors within population subgroups (such
as age, sex, race, and level of physical activity), inherent
performance characteristics of the ECG for the identiﬁca-
tion of prognostically important abnormalities, quality of
interpretative analysis, and balances among beneﬁts, risks,
and the costs of derived information.
The usefulness of the ECG for detection of disorders such
as inherited channelopathies and cardiomyopathies is
strongly dependent on test sensitivity, speciﬁcity, and
positive and negative predictive values. However, even
effective screening ECGs for the identiﬁcation of diseases
with low prevalence in the general population is not
equivalent to identifying individuals who will actually
experience clinically adverse outcomes, because the inci-
dence of SD will be substantially lower than the prevalence
of disease. The posttest predictive value of the ECG for
disorders of low prevalence will necessarily be low, as a
simple function of Bayesian analysis (187,188). However, a
low positive predictive value of a test is alone not sufﬁcient
to invalidate its screening value if clinically useful and
cost-effective methods can reliably separate true-positive
from false-positive test results, if interventions can reduce
risk, and if society places a high enough value on the pro-
cess to accept the associated costs in terms of the life-years
saved. In terms of HCM, the single most common cause of
athletic ﬁeld deaths (1,2,6,117,122,125a,127), there is
particular concern about relying on a single screening ECG
obtained at a single point in time to exclude this disease,
given the distinct possibility of left ventricular remodeling
and changes in pattern in the ECGs in young patients{References 3,5,28,55,64,79,98,100,103,179–184.
#References 3,15,17,23–25,28,29,59,64,74,88,89,184,186.(108,119). This is a potential source for false-negative di-
agnoses (15,93,185,189,190).
Technical Factors
Similar to many tests, the ECG is subject to issues related
to consistency, reproducibility, and interobserver vari-
ability in interpretation. Indeed, performance of the ECG
in a real-world mass screening setting will vary when
readers and technicians with vastly different expertise
and efﬁciency are confronted with large numbers of
studies to perform and interpret rapidly. Computerized
electrocardiography can aid in the standardization of
measurements by analyses obtained simultaneously with
superimposed 12-lead complexes. Central databases of
high-quality ECGs with directly comparable methodology
will ultimately promote improved separation of normal
from abnormal ECGs in relevant populations.
Interpretation of the ECG is based on measurements
and the integrative examination of waveform shapes. The
usefulness of established criteria for interpretation de-
pends on the accuracy of the recorded signal; however,
there are technical sources of potential nonbiological
variability that limit the reliability of measurements,
distort waveforms, reduce reproducibility, and blur the
distinction of normal from abnormal tracings (191,192).
Among the most important of these is operator selection
of inadequate bandwidth for the ECG (193–195). In chil-
dren and adolescents, inappropriate low-pass ﬁltering
(high-frequency cutoff <250 Hz) limits noise in the
recorded signal but reduces the amplitude of R waves
used to estimate ventricular mass (195–197), whereas
inappropriate high-pass ﬁltering (low-frequency cutoff
>0.05 Hz or its digital equivalent) limits baseline wan-
dering but can introduce artifactual deviation of the J
point and ST segment (198,199).
A major source of potential technical error is mis-
placement of the limb or precordial electrodes, not
uncommonly including inadvertent lead reversals (200–
206), in which the V1 and V2 leads are placed in the second
(rather than the fourth) intercostal space and the left
precordial V5 and V6 leads are placed below the horizontal
extensions of V4 in the ﬁfth intercostal space (205,207).
Precordial lead misplacement results in distorted pre-
cordial R-wave progression, thereby simulating ante-
roseptal infarction; magniﬁes otherwise small terminal R0
deﬂections and elevates the ST segments in V1 and V2; and
confuses standard criteria for diagnosis of ventricular hy-
pertrophy (208–210). Because day-to-day lead misplace-
ment itself often varies, reproducibility of the precordial
ECG is poor, and this variability can limit the ability
to separate normal from abnormal tracings (192,208).
Another source of variability in assessment of the ECG
involves standardization of interval durations, which
have changed with newer technology (192,211). Evolution
**References 33,52,57,71,88,91,172,179,180,219,223–231.
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ography has altered observed QT intervals (and QRS du-
rations) from the established normal limits that were
derived from single-channel (lead) recordings. Difﬁculty
in measuring the QT interval with precision has obvious
relevance to the reliable identiﬁcation of LQTS as part of
mass population screening ECGs (184,211–213).
It is also difﬁcult to establish generally accepted and sex-
adjusted upper limits of normal for QT duration suitable for
LQTS screening in general populations. For example, even
though risk of SD increases with the duration of the QT
interval, there is important overlap inQT ranges for healthy
normal subjects and genetically affected individuals.
There are also technical issues that explain variations in QT
partition values, and reliance on computer-generated
diagnostic interpretation of ECGs alone will fail to identify
many family members at risk for LQTS (212–214).
QT and other intervals were originally measured from
single leads, often limb lead II or V5, from the onset of the
QRS to the point at which the T wave joined the baseline
or at which a tangent from the descending limb of the T
wave met the baseline. By deﬁnition, single-lead mea-
surements tend to underestimate the true QT interval,
because the onset or offset of waveforms may be iso-
electric in any given lead (215), whereas the lead with the
earliest QRS onset may be different from that with the
latest T-wave end (212). Measurement of the true duration
of an interval on the ECG requires examination of all leads
at once to detect the earliest and latest ﬁducial points.
This type of global interval measurement of QT will be
systematically longer than QT intervals of individual
leads, perhaps by as much as 30 to 40 ms (215).
In addition, a variety of QT-interval rate-correction
formulas have been proposed, and these produce
different results, so that Bazett-corrected values cannot
be intermixed with Fridericia-corrected measurements
(216–218). Because automated algorithms for determining
ECG waveform ﬁducial points on the ECG vary (191),
measurements used in mass screening for cardiovascular
disease must be interpreted in the context of evolving
changes in duration standards. In this context, it is
essential that population studies with ECGs provide
explicit description of the methodology used to deter-
mine normal limits and harmonize measurements and
limits with the referent populations.
Reliability of ECG Diagnostic Criteria
A major obstacle in screening is the overlap in measure-
ments with the ECG between healthy subjects and those
with prognostically important cardiac disorders, which
may involve measurements of amplitudes, interval du-
rations, and waveform shape. Furthermore, the spectrum
of alterations in the ECG in healthy young athletes and
nonathletes can overlap and in some cases (5% of eliteathletes) (190,219) are indistinguishable from those in
patients with cardiovascular diseases that cause SD
(particularly HCM) (219). The sensitivity of screening
ECGs for the various channelopathies, preexcitation syn-
dromes, and cardiomyopathies can be difﬁcult to estab-
lish with precision, because disease severity within
populations affects the prevalence and extent of abnor-
malities on the ECG and because phenotypic expression
of these disorders is heterogeneous.
Therefore, screening is complicated by the potentially
pathological or nonspeciﬁc patterns in the ECGs that
occur in general populations, particularly in trained ath-
letes (179,180,182,183,219–227). In this regard, in 2010 the
ESC offered revised recommendations for deﬁning ab-
normalities in ECGs in trained athletes (183), with the
intent to create a mechanism for reducing expected false-
positive results (and increasing speciﬁcity) in pre-
participation screening ECGs, that is, from unacceptably
high rates of up to 15% to 20% to rates of #5%.** This
strategy has been based in part on the assumed premise
that in young athletes and other young people, isolated
increases in QRS voltages (in the absence of other pattern
alterations) have limited speciﬁcity and are unlikely to be
indicative of pathological hypertrophy (e.g., as encoun-
tered in HCM) (125a,183).
There have been several efforts to reduce the possibility
of false-positive interpretations of ECGs and increase
speciﬁcity by redeﬁning standards in the ECGs. These have
been largely through non–peer-reviewed panel proposals,
which are essentially declarations largely unsubstantiated
by speciﬁc data. The Seattle Criteria (82,230), which are
very similar to the 2010 ESC guidelines (183), have been
promoted in this regard. However, such panels have sig-
niﬁcant potential limitations, given that their recommen-
dations are not based on independent cohort studies in
sizable general populations interrogated systematically
with both electrocardiography and echocardiography
(80,81,224). Notably, in the largest sampling reported to
date, a population from the United Kingdom (n ¼ 7,764)
that consisted of individuals who were sedentary or
participating in recreational physical activity, fully 22%
had patterns in the ECGs considered pathological by ESC
2010 criteria (183,231). These data clearly argue against,
and essentially preclude, the feasibility of screening a
general population with ECGs for cardiovascular
abnormalities.
By reclassifying patterns in the ECGs in 508 college
athletes based on the revised 2010 ESC criteria for ECGs,
Weiner et al. (180) showed that the number of false-
positive results in the ECGs could theoretically be reduced
from 16% to 10%. However, validation of the 2010 ESC
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populations <35 years of age (with and without cardiac
disease and including athletes) to establish the true
sensitivity and speciﬁcity of the revised criteria.
Finally, the recent recognition that early-repolarization
(J wave) syndrome may be relevant to young people as a
cause of SD potentially adds considerable complexity to
the application of the ECG to mass screening of athletes
for a number of reasons, particularly the reliability and
reproducibility of pattern interpretation (229,232–234).
The potential signiﬁcance of this alteration in ECGs to
population-based preparticipation screening is unre-
solved at present (232–234).
Sensitivity and Speciﬁcity (False-Positives and False-Negatives)
The sensitivity and speciﬁcity of the ECG for detection of
cardiovascular disease will vary with the severity of
phenotypic expression. In HCM, for example, speciﬁcity is
reduced (and false-positive results increased) with only
modestly increased voltages in the ECGs and repolarization
abnormalities, which are not uncommon in this age group,
particularly among trained athletes and black males.yy
Furthering the sensitivity and speciﬁcity of fully expressed
preexcitation in large, healthy screened populations will
be reduced by the changing day-to-day fusion of normal
and accessory pathway conduction, which commonly re-
sults in an entirely normal tracing, and the questionably
slurred waveform upstrokes that occasionally are evident
in the mid precordial leads of healthy normal subjects.
It is well recognized that physiological (training-
related) alterations in the ECGs often overlap with path-
ological patterns frequently in physically active children
and adolescents.zz Speciﬁcally, a myriad of potentially
important pattern alterations in the ECGs occur in a sig-
niﬁcant minority (10%–20%) of athletic individuals, with
the proportion dependent on the precise deﬁnition of
“abnormal” used.xx In >1,000 elite athletes without
echocardiographic evidence of cardiovascular disease,
Pelliccia et al. (219) found 14% had distinctly abnormal
patterns in the ECGs that were highly suggestive of
pathological conditions (including HCM) (119,185) and
thus were false-positive test results. In a large population
of trained athletes from the United Kingdom (n ¼ 4,081)
(231), fully one third of the ECGs were judged to be
pathological on the basis of 2010 ESC criteria (183).
Indeed, most of these patterns will, by Bayesian neces-
sity, be false-positive results, because the prevalence of
prognostically important channelopathies, cardiomyopa-
thies, and other conditions is much lower than theyyReferences 180,185,219,225,227,235,236.
zzReferences 33,182–184,219,221,224,236–242.
xxReferences 3,5,23,24,29,33,48,64,76,180,183,219,223.prevalence of pathological ECGs (33,187,188,235). Notably,
repolarization abnormalities in the ECGs that involve
T-wave inversion and are identiﬁed during screening
in apparently normal athletes have been shown to occa-
sionally predict future development of HCM or ARVC/D
phenotypes, which underscores the potential value of
long-term surveillance (236). These observations, although
rare, support consideration for repetitive screening
examinations.
It is necessary to place the debate about false-positive
results on ECGs into perspective,kk particularly in the
context of large-population screening programs. At a high
enough rate, false-positive ECGs can create excessive and
costly second-tier testing (e.g., with echocardiograms and
magnetic resonance imaging), and in the process greatly
exceeding true-positive results (3,28,93,97). However,
even if ECGs with false-positive results could be reduced to
only 5% in the course of screening 10 million individuals
(the estimated number of U.S. competitive athletes),
screening ECGs would nevertheless identify a formidable
obstacle of 500,000 people who required further testing to
exclude underlying heart disease and resolve eligibility for
sports participants. Very few of these individuals would
ultimately prove to have important disease with a risk for
SD that required disqualiﬁcation (113,237).
Often ignored in this discussion is the importance of
false-negative test results in the ECGs, which reﬂect low
sensitivity (93,97,125,127,189,190). In the current envi-
ronment, false-negative results can be expected in $10%
of patients with HCM (the most common cause of SD in
young people), with a signiﬁcant proportion of these
showing completely normal patterns (189). In addition,
$90% of those with congenital coronary anomalies (the
second most common cause of SD in young athletes) will
have a normal ECG (118). Even in the case of LQTS, for
which the 12-lead ECG is the only clinical test that reliably
detects the disease phenotype, z25% to 30% of geneti-
cally affected individuals will have a normal or borderline
corrected QT interval, although this percentage is highly
dependent on the upper limit of QT duration selected. As
in any systematic screening context, the overall beneﬁts
of screening ECGs for detection of cardiovascular disease
are limited by false-negative test results.
It is evident and commonly accepted that no screening
strategy can be considered absolute (i.e., 100%) in its
ability to detect those cardiovascular diseases responsible
for SD in young people. Indeed, a 26-year study of Min-
nesota athletes (with autopsy examinations) (127,129)
showed that only 40% of SDs were attributable to diseases
that could be detectable reliably by preparticipation
screening even with 12-lead ECGs, which translates tokkReferences 91,97,98,109,189,225–229.
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year.
There have been several recent efforts, largely from the
primary care community in the United States, to improve
test speciﬁcity of the ECGs and recognition of true
abnormalities.{{ These initiatives, which attempt to
reduce high false-positive rates that can encumber the
principle of large-population screening ECGs, have
been successful in improving the separation of normal
from abnormal ECGs by reducing false-positives to a range
of <5% to 10% in some analyses. However, improving the
speciﬁcity of interpretation of the ECGs in this way may
result in a decrease in sensitivity of the test (i.e., greater
numbers of false-negative results), which in fact represent
athletes with potentially lethal cardiovascular diseases
such as LQTS and HCM that the screening initiative is
designed to recognize and protect (71,125,179,180,189,223).
Therefore, this strategy to reduce false-positive results
could be regarded as an unfavorable tradeoff in screening.
Positive and Negative Predictive Values
The positive predictive value of a test is the proportion of
true positive outcomes among all positive tests in a study
population. The negative predictive value is the propor-
tion of true negative outcomes among all negative tests
(188). Predictive value depends to a great extent on the
incidence of the disease in the population, which is
assessed by the test.
For screening tests such as the ECG, the positive pre-
dictive value for disease is less dependent on test sensi-
tivity than on its speciﬁcity. The positive predictive value
of a test (such as the ECG) with imperfect speciﬁcity is
poor when the population prevalence of the disorder be-
ing tested is low, as is the case for all cardiovascular ab-
normalities associated with SD in young people. Even a
test with nearly perfect speciﬁcity will have more false-
positive than true-positive responses when prevalence of
disease in the population is <10% (187).
With a prevalence of disease <1%, and perhaps <0.1%
for even the most common channelopathies and inherited
forms of cardiomyopathy (i.e., HCM), the positive pre-
dictive value of the ECG is small or trivial. When the
prevalence of rare causes of adverse outcome in young
people is as low as 0.1%, the negative predictive value of
the ECG nevertheless remains high irrespective of test
sensitivity. Indeed, the negative predictive value for
extremely low-prevalence events is a questionable sta-
tistical concept, because nearly all subjects in the normal
screening population will almost certainly remain free of
adverse outcomes.{{References 30,33,52,80–82,180,183,230.Impact of Age and Growth
Deﬁning an abnormal ECG is particularly difﬁcult in
growing children and adolescents because of changes in
heart rate, QRS axis, ventricular predominance, intra-
ventricular conduction, and repolarization morphology.
By z16 years of age, patterns in the ECGs become similar
to those of adults; therefore, normal versus abnormal
distinctions in adolescence are often challenging for
pediatricians, working at one end of the age spectrum,
and for general practitioners and internists working at
the other end of the age range. Certainly, in any hypo-
thetical large-population or national screening program,
interpreters of ECGs would be required to be familiar with
ECGs in adolescents.
Finally, real-world difﬁculties in test interpretation can
be expected in mass screening if the 12-lead ECG is used to
detect (or raise suspicion) of those diseases that cause SD in
young people and athletes (184,213). In 1 study, expert
pediatric cardiologists blindly interpreted ECGs from
young, nonathlete patients with HCM, LQTS, and other
conditions (184). False-positive rates in the range ofz30%
were reported and were lowest for LQTS, Wolff-Parkinson-
White, and HCM; 40% of the HCM patients were missed
(i.e., false-negatives) in the process. Indeed, in another
study, correct classiﬁcation of QT intervals from patients
with or without LQTS was achieved by 96% of QT experts
and 62% of arrhythmia experts but by <25% of general
cardiologists and noncardiologists (213).
Race and Sex
It is becoming apparent that sex, race, and ethnicity are
important determinants of pattern in the ECG (6,117,225–
227,238–242). Notably, ethnic and racial differences are
underscored byMagalski et al. (225), who found potentially
pathological patterns in ECGs in 30% of black professional
football players compared with only 13% of whites, a dif-
ference that was independently associated with race. T-
wave inversions in anterior leads V1 through V4 have been
cited as unique ethnic variants in the ECGs that occur in
male athletes of African/Afro-Caribbean origin (239–241).
Similar ﬁndings have been reported by Choo et al. (226) in
1282 National Football League players. Recently, ECGs
were abnormal in 40% of >1,200 young black athletes in
the United Kingdom, according to 2010 ESC criteria (183),
raising suspicion of cardiac disease (241).
Therefore, screening ECGs can be inﬂuenced by racial
distribution, which can potentially inﬂate false-positive
rates (89,225,227,238–242); this resonates for African and
other black athletes, in whom left ventricular wall thick-
ness can exceed that of white athletes (238,240). These
factors could potentially trigger a cascade of unfortunate
events that would generate an overdiagnosis of HCM, as
well as unfair and unnecessary disqualiﬁcation from
competitive sports. However, an undercurrent of mistrust
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tive athletes may exist in certain minority communities.
Because ECGs in female athletes are overwhelmingly
normal or near normal, their risk of false-positive test
results on the ECGs is likely to be decreased compared
with males (219,223).SCREENING ECGs AND
CLINICAL OUTCOME/MORTALITY RATES
A distinctive body of literature has emerged from
several countries describing preparticipation screening
strategies, speciﬁcally assessing the impact of screening
ECGs on mortality in athlete populations.## However, at
present and importantly, there is no consensus from these
data to support the principle that the addition of 12-lead
ECGs to history and physical screening actually reduces
mortality.
The Italian (Veneto) Experience
The sole evidence that amandatory screening strategywith
a resting 12-lead ECG reduces SDmortality in young people
comes from the study of competitive athletes in the Veneto
region of Italy conducted byCorrado et al. (4,18,31). It is this
publication, with its descending mortality curve, that has
driven the debate over the screening strategy of ECGs and
triggered (if not created) the substantial interest in this
area. Since 1982, Italian law has mandated an ambitious
national program with clinical screening evaluations for
cardiovascular disease in all individuals aged 12 to 35 years
engaged in organized competitive sports (4,18,244). This
screening process is subsidized in part by the national
health system and performed by accredited sports medi-
cine physician specialists working in dedicated sports
medicine centers. The standard evaluation includes per-
sonal and family history, physical examination, and resting
12-lead ECG (and step stress test). Eligibility for competi-
tive sporting activity is dependent on a normal screening
evaluation that excludes cardiovascular disease, although
additional specialized noninvasive testing (e.g., echocar-
diography) is required when abnormal ﬁndings are iden-
tiﬁed on the primary evaluation. Disqualiﬁcation from
participation in competitive sports is governed by restric-
tive Italian guidelines if evidence of heart disease is
identiﬁed (237).
In 2006, Italian investigators reported the impact of
their mandatory screening program with ECGs on the
mortality of young competitive athletes, (12–35 years old)
(4). Although the Italian model is a truly national initia-
tive (4,18,31,116), the highly visible published data come##References 4,18,28,88,109,130,190,243.only from a relatively small region of this country (Ven-
eto), which in fact constitutes a small proportion of the
overall Italian population (9%). Therefore, it is unknown
to what extent the Veneto data (4) are representative of
Italy overall.
Corrado et al. (4) compared mortality rates in athletes
before the introduction of mandatory screening ECGs
versus mortality evident after implementation of the pro-
gram. The prescreening period was only 2 years in duration
(1979–1981), whereas the postscreening period was much
longer (22 years; 1982–2004). The authors reported an
impressive 90% decline in SD rate, from 4.3 per 100,000
person-years in the prescreening period to 0.87 per
100,000 person-years with screening ECGs. This striking
mortality reduction was attributed by the authors entirely
to routine inclusion of the ECG into the screening process.
However, these retrospective, nonrandomized data are
based on a low event rate, with 55 cardiovascular deaths in
26 years (only 2 per year) as the numerator. The estimated
denominator of at-risk individuals was extrapolated and
interpolated from census data obtained only every 8 years,
and without prospectively established interpretation
criteria for the ECGs. Therefore, the striking downward
linear curve is seemingly not primarily a function of a
decrease in events, but rather in part the change in esti-
mated participation rates of at-risk athletes.
These data are potentially very important and justify
further study but to date have not been replicated. Indeed,
a subsequent study comparing preparticipation screening
in competitive athletes from Veneto (ECG) and Minnesota
(history and physical examination over the 11-year period
of 1993–2004) showed low SD event rates and no differ-
ences in mortality (0.93 in Minnesota versus 0.87 in Ven-
eto) despite the different strategies used (130).
The SD incidence in Veneto of >4 per 100,000 person-
years at the onset of mandatory screening (4) is consid-
erably higher than any other reported mortality rate in
young athletes in the literature. Given that the brief pre-
screening phase occurred fully 2 decades before Corrado
et al. (4) retrospectively evaluated their population,
methodology could potentially have contributed to un-
derestimation of the denominator, an exaggeration of the
mortality rate at that time, and ultimately, the marked
downward trend in survival otherwise attributed to
screening ECGs. It is also possible that athletes who were
potential candidates for inclusion in the cohort but who
had more advanced disease could have died before
screening was performed, whereas those who survived
and were available for screening constituted a lower-risk
subset (245). Finally, these data are based largely on SDs
from arrhythmogenic right ventricular cardiomyopathy,
the most common cause of these events reported from
Italy (131). This represents a very different epidemiology
of SD than in the United States, where HCM predominates
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making direct comparisons of screening strategies and
mortality data between Italy and the United States or
other countries.
The studies by Corrado et al. (4,18,31) prompted ESC
recommendations advocating mandatory screening ECGs
for athletes in other countries and in fact has launched
an entire impetus for preparticipation mass screening of
athletes (5). However, other independent reports have
shed a different light on the potential efﬁcacy of mass
screening ECGs to reduce mortality and questioned the
advisability of such a strategy.
The Israeli Experience
Participants in organized sports activities in Israel are
required to undergo medical screening that includes a
12-lead ECG (28,93). The Israeli Sport Law, enacted in
1997, deﬁnes athletes requiring screening as those “in-
dividuals engaged in sport activities at any level of
physical endurance,” from amateur sportsmen to profes-
sional athletes (246). The law also dictates that only
physicians certiﬁed by a specialized accreditation course
can perform screening examinations. Athletes with
abnormal screening tests are referred to expert cardiolo-
gists or electrophysiologists at the discretion of screening
physicians. Similar to Italy, there is no centralized na-
tional registry or collection of data in Israel, and conse-
quently, information is lacking regarding the percentage
of athletes who are referred for additional testing, or are
eventually disqualiﬁed.
As in the Italian study, the impact of screening ECGs on
SD risk has been estimated in Israel by comparing the
incidence of events before and after implementation of the
law that mandated screening (28). However, in contrast to
the Italian data, which compared a 2-year prescreening
period with a 22-year postscreening period, the Israeli
study had the advantage of comparing prescreening and
postscreening periods of similar duration (12 years each).
Limitations of the Israeli study include estimation of the
number of cardiac arrest events (the numerator) from ac-
counts in only 2 newspapers (which could invite under-
reporting) and derivation of the number of people at risk
(the denominator) from surrogate participation rates, as
well as the absence of forensic-based diagnoses.
The average annual mortality incidence before and af-
ter implementation of mandatory screening ECGs was
essentially the same: 2.54 and 2.66 per 100,000 person-
years, respectively (p ¼ 0.88), consistent with screening
having no apparent effect on the mortality rate of ath-
letes. Notably, if the Israeli cardiac arrest event rates
during the 12 years after screening had been compared
arbitrarily with a limited 2-year period immediately
before screening (when there was a substantial increase in
mortality), the conclusion would have been the same as inthe Veneto study, that is, that mandatory screening ECGs
signiﬁcantly reduced SD incidence among athletes. This is
because the event rate just before the start of screening
was substantially higher than at any other time during the
24-year study period.
This increase in SD rate that occurred in both Italy and
Israel just before implementation of the legislation that
mandated screening ECGs was likely caused by random
ﬂuctuations in this rare phenomenon, with clusters of SDs
that happened to occur in 1980 to 1982 in Italy and in 1994
to 1995 in Israel. Such peak occurrence may have captured
public attention through the media, in turn promoting
legislation mandating screening ECGs. A subsequent
“regression to the mean” statistical phenomenon would
then produce a reduction in event frequency toward the
long-term average that instead might be attributed to the
screening program ECGs (247).
The U.S. Experience
There have been no national screening programs in the
United States similar to those in Italy and Israel. Early
screening efforts in relatively small college athlete or
school-aged populations with ECGs or echocardiography
generally reported low yields of important cardiovascular
diseases (88,89,91,225–227,243). However, cardiovascular
mortality in Minnesota state high school athletes proved
to be particularly uncommon (<1/year on average).
The Danish Experience
Danish law dictates that forensic examination must be
performed for all sudden and unexpected deaths and that
death certiﬁcates must provide detailed information
concerning the circumstances and causes of death. Holst
et al. (100) took advantage of these data to estimate SD
risk for the athlete and nonathlete populations of
Denmark, a country where screening of athletes is not
performed. The incidence of sports-related SD in
Denmark is 1.21 per 100,000 person-years (100), similar to
the rate reported for Italy after many years of screening
ECGs (0.87/100,000 person-years) (4,130) and in Minne-
sota with screening performed only by history and phys-
ical examination (0.93/100,000 person-years) (130), and
lower than the SD rate in the Danish general population of
the same age (3.76/100,000 person-years) (100).
UNITED STATES VERSUS ITALY:
GLOBAL CONSIDERATIONS AND COMPARISON
OF PRIOR ATHLETE SCREENING DEMOGRAPHICS
Given the controversy generated over current screening
strategies in Italy (as a proposed model) and in the
United States, it is worth underscoring certain distinct
differences between the 2 countries. First, the population
of the United States is 5-fold larger than that of Italy (313
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Furthermore, the United States is 30 times larger in land
mass than Italy, which presents an obstacle that impacts
the practicality and durability of large-scale screening.
Second, the U.S. population is substantially more diverse
ethnically and racially than that in Italy, a crucial vari-
able when one interprets patterns in ECGs in athletes
or other young people for a variety of cardiovascular
diseases, given the known differences in ECG
“normality” based on ethnicity, race, age, and sex
(219,225,227,238–241). This is notable with regard to the
substantial population of blacks, for whom there is evi-
dence of signiﬁcant differences in patterns in the ECGs
and left ventricular wall thickness compared with
whites. Third, the U.S. healthcare system does not
include (and realistically cannot create) specialized
practitioners dedicated to mass screening, such as those
employed in Italian athlete screening since 1982
(4,18,31,116). Indeed, the global economic climate,
heightened sensitivity to discriminatory practices, and
numerous competing healthcare priorities represent
major obstacles to a national mass screening program for
the United States, and probably would also for Italy (and
other European countries) if such an initiative were
proposed today for the ﬁrst time.
To the best of our knowledge, despite the study about 8
years ago by Corrado et al. (4,18) and the ESC recommen-
dations (5), the Italian model of systematic national car-
diovascular screening with ECGs for athletes at all levels of
competition presently exists elsewhere only in Israel, and
has not been adopted in any of the other 51 European
countries; also it has been rejected by Denmark (100). To
date, no national organization in the United States,
including the National Institutes of Health, has endorsed
such a screening program with ECGs (23).
However, in the United States, it is customary practice
(although not required by law) to routinely screen all high
school and college-aged athletes for cardiovascular dis-
ease (albeit without ECGs) (20,22,177). Indeed, there are
only 3 countries (Italy, Israel, and the United States) in
which the practice is to systematically screen all young
athletes regardless of their level of competition,
achievement, or expertise.
On the other hand, there have been recent initiatives,
largely conﬁned to the minority of athletes with elite or
professional status, to screen for cardiovascular disease
(often with ECGs), with uncertain levels of compliance,
i.e., in several European countries: France, Spain,
Portugal, Greece, Germany, Sweden, the United Kingdom,
Belgium, and the Netherlands. The situation is much
different in Denmark, where screening of athletes (and
nonathletes) is not performed with either history and
physical examination or ECGs because of the low inci-
dence of SD in this population (100).UNIVERSAL SCREENING AND
RESOURCE ALLOCATION
In addition to the aforementioned scientiﬁc limitations,
there are a number of practical issues that together
represent serious impediments to all large-scale, general
population screening initiatives with ECGs. For example,
the resources necessary to create de novo and maintain a
mandatory mass screening program effort throughout an
entire country would represent a problem of feasibility
and quality control. For example, it is likely that an in-
dependent infrastructure would be required with desig-
nated testing centers and dedicated professional
personnel (as in Italy). The use of preexisting but already
busy facilities and personnel dedicated to patients with
other medical problems in order to perform thousands of
additional screening examinations would likely consti-
tute a burden to an already overworked system. The
establishment of new screening centers within a
geographic area as large as the United States, in which
z20% of the population resides outside of large metro-
politan areas, would be daunting.
Mandated screening programs would also have
resource costs, including purchase and maintenance of
equipment; selection and training of professional
personnel to perform and interpret the tests; availability
of administrative staff for scheduling and generating test
reports, as well as correspondence regarding test inter-
pretation; follow-up referrals to cardiologists for second-
tier subspecialty evaluation with noninvasive testing;
establishment and maintenance of electronic data stor-
age; and negotiations with insurance carriers to resolve
coverage issues and legal fees.
In such a program, physicians responsible for inter-
pretation of ECGs would need to have expertise in reading
pediatric ECGs, according to standardized criteria (which
in turn would have to be developed). In past feasibility
screening studies, physician interpreters of ECGs (and
other personnel) have participated largely on a volunteer
basis; however, a formally mandated mass screening
program would require contractual arrangements that
addressed compensation and malpractice coverage,
thereby adding signiﬁcantly to the cost. The professional
and economic burden imposed on the healthcare system
by mass screening may be illustrated as follows: Pediatric
cardiologists would be the most qualiﬁed to perform these
examinations and interpretation of the ECGs, but there
are only 1,500 of these practitioners in the United States,
who, if commissioned, would be required to interpret
several thousand ECGs in a given year, even if the pro-
gram was somehow limited to competitive athletes in the
United States.
Secondary (or second-tier) subspecialty evalua-
tions with echocardiography and other testing (e.g.,
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assess a diverse array of potential diseases represent the
Achilles heel of mandatory mass screening by adding
considerably to the complexity and cost of any broad-
based screening program, given the anticipated not
inconsequential false-positive rate. This “downstream
effect” of primary screening could lead to unnecessary
and unwarranted restrictions and disqualiﬁcations from
sports, anxiety and potentially adverse psychosocial
consequences, and impediments to insurability or
employment opportunities (3). It is this expensive
“downstream” testing mostly in false positives that is
potentially the major contributor to cost inefﬁciency in
any large screening program.
Even after such systematic additional testing, cardio-
vascular disease cannot be excluded reliably in all cases,
and some uncertainty in the risk assessment would al-
ways remain. Also, in a theoretical government-spon-
sored screening program, the responsibility for
enforcement of disqualiﬁcation from competitive sports
would fall largely to the individual screening physicians,
as would the risk of litigation.
COST, CHARGES, AND COST-EFFECTIVENESS
Although it is not possible to place a speciﬁc monetary
value on a young life terminated suddenly and prema-
turely by underlying (and unsuspected) heart disease, cost
is nevertheless an unavoidable concern when one de-
liberates the merits of large-scale screening programs.
Cost-efﬁcacy data have potential value in healthcare policy
decisions. All such cost-effectiveness studies must be
regarded as highly theoretical estimates, because they are
unavoidably based on numerous contestable assumptions.
Furthermore, 2 principal limitations arise in the appli-
cation of cost-effectiveness analysis to screening ECGs in
youthful populations (92): 1) incomplete registry data to
deﬁne the incidence of SD in this age group, and 2) absence
of large randomized trials that test the hypothesis that
screening reduces the frequency of SD events. By deﬁni-
tion, a screening strategy cannot be cost-effective if not
ﬁrst demonstrated to be clinically effective.
A commonly accepted benchmark for cost-effectiveness
in the United States is <$75,000 per year of life saved,
whereas a cost of $75,000 per year is regarded as ineffective
(247a). However, these analyses must be viewed as speciﬁc
to the healthcare system and disease; for example,
screening is generally less cost-effective in the United
States because the tests are more expensive (247a,248).
There are conﬂicting data estimating the cost per year
of life saved in screening models with ECGs that justify
closer scrutiny (92,101,228,248–251). Wheeler et al. (248)
calculated this measure for U.S. competitive athletes.
Although this assessment is useful, it potentiallyunderestimates costs by using the data from Veneto to
estimate risk (given that it is modeled largely on mortality
attributable to ARVC/D and not HCM. Very conservative
estimates of costs for diagnostic testing were offered in a
population of 3.7 million athletes (approximately one
third the number in the United States), with infrastruc-
ture and administrative costs absent from the model.
Nevertheless, the addition of an ECG to a cardiovascular-
focused history and physical examination was projected
to save 2.06 life-years per 1,000 athletes at a cost of
$42,000 per life-year saved. This calculation suggests that
the cost-effectiveness of testing ECGs could exceed that
of history and physical examination alone and fall within
the traditional and socially acceptable norm. History and
physical examination screening alone was not cost-
effective, and notably, in this model, annual screening
ECGs of large cohorts or general populations of young
people (not restricted narrowly to athletes) was not
considered to be cost-effective (248).
One study of 1,473 NCAA Division I college athletes over
5 years measured the cost of adding ECGs to the screening
history and physical examination (228). Using the criteria
of the ESC pertaining to ECGs, the cost per abnormal
ﬁnding ($68,836) did not differ signiﬁcantly between the
strategies of history and physical examination alone versus
the addition of ECGs. The ECG was more sensitive, identi-
fying 8 more cardiac abnormalities than the 5 detected by
examination; however, only 1 of these abnormalities could
be considered clinically signiﬁcant (LQTS); the false-posi-
tive rate was high (19%), and 2 athletes were disqualiﬁed.
The total cost of the 5-year university-based program,
including all follow-up testing, was z$900,000. A previ-
ous study by Fuller (251) did not provide effectiveness data
but estimated the cost per life-year saved of different
screening modalities to be as follows: history and physical
examination, $84,000; 12-lead ECG, $44,000; and 2-
dimensional echocardiography, $200,000.
In contrast, a recent theoretical model judged the addi-
tion of ECGs to the preparticipation history and physical
examination for athletes as not cost-effective, with
excessive costs driven by false-positive ﬁndings (250) and
with a calculated cost of $900,000 for a single averted SD. A
rigorous simulation model that estimated cost versus
beneﬁt for screening ECGs to detect causes of SD in children
and adolescents concluded that the anticipated cost would
be high relative to the potential health beneﬁts, with an
unfavorable cost-effectiveness ratio (250). Finally, a recent
cost-projectionmodel from Israeli investigators found that
replicating the Italian strategy for screening ECGs in the
United States would result in enormous costs per life saved
(up to $14 million per athlete), with total costs of many
billions of dollars per year (92).
Given limited healthcare resources and an aging pop-
ulation that requires increasing amounts of medical care,
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1497it is of importance to consider the absolute cost of a
nationwide mass screening program. The substantial cost
of outpatient screening within the U.S. healthcare system
must be borne by the individual patient or private or
public sources, because most insurance carriers will not
cover expenses related directly to such routine examina-
tions. This situation differs measurably from that in Italy,
other European countries, and Canada, where the
healthcare systems are largely socialized.
In 2007, an AHA panel addressed the absolute cost for
the screening of athletes (3). If one assumes there are
z10 million U.S. high school and college athletes to be
screened with ECGs, using estimates based on data from
the Centers for Medicare & Medicaid Services for exami-
nations and testing (as well as substantial start-up, infra-
structure, and administrative costs), the conservative
overall cost for such a program would be at least $2 billion
per year to start and somewhat less annually thereafter.
The precise amount depends on the frequency of exami-
nations in a given program and whether it would be
necessary to screen each athlete every year. Based on a
recent screening experiment in Texas, workingwith a grant
award of $1 million, a state-funded pilot project (252) was
able to screen only a total of 2,350 school children aged 11 to
17 years and found just 1 new patient with HCM and 9 with
mitral valve prolapse (252). If these costs are extrapolated,
$40 million would be required to screen 100,000 students.
To place absolute cost into perspective, the $2 billion
per year exceeds the annual budget of most major U.S.
medical centers and is similar to that for the National
Heart, Lung, and Blood Institute. Therefore, public health
efforts targeting other prevalent problems in this age
group that account for many more deaths annually, e.g.,
driving while intoxicated or distracted, drug use, or sui-
cide, would likely be far more cost-effective. This discus-
sion of cost and resource limitations is focused on the
United States but in principle may also be relevant to other
countries considering mass screening ECGs at this time.
INSIGHTS FROM PRIOR SCREENING STUDIES
WITH ECGS
A literature search identiﬁed 17 published studies
including 89,697 healthy subjects that reported the re-
sults of large screening initiatives with ECG, echocardi-
ography, or both (as well as history and physical
examination***; Table 2). Each of these studies was
designed to detect a variety of largely genetic/congenital
cardiovascular diseases, targeting predominantly adoles-
cent and young adult participants in organized competi-
tive sports ranging from high school to the professional***References 66,88,89,91,94,96,97,104,223,225,228,229,253–256.level. These athletes were most commonly in basketball,
football, and soccer. The majority of reports were from
the United States (60%), but others came from Italy, the
United Kingdom, Spain, Germany, and China; several
were biracial. The athletes reported in these studies
represent a heterogeneous group in terms of duration and
intensity of training and level of performance, as well as
age, sex, race, and other variables, but appear to generally
be in accord with the 36th Bethesda Conference deﬁnition
of a competitive athlete (7,113).
The percentage of athletes reported with abnormal
ﬁndings on ECGs during screening initiatives varies
widely from 2.5% in 1 study of high school athletes (229) to
35% in professional athletes (225), with the average being
z12%, greatly dependent on the precise criteria used to
deﬁne abnormal patterns in the ECGs (Table 2). Notably,
the vast majority (probably >90%) of abnormal ECGs in
these populations represent false-positive test results.
The frequency of cardiac abnormalities was on average
z5% for those detectable by history alone and z2.5% for
those suspected on the basis of physical examination.
These screening studies reported a relatively low yield
of highest-risk cardiac diseases. For example, among the
nearly 90,000 athletes screened, there were only 6
deﬁnitive diagnoses of HCM (91,94,104,255), although 38
other athletes with increased septal thickness >13 mm
were noted (Table 2). Explanations for the low frequency
of HCM diagnoses are elusive, given that a number of
independent surveys worldwide have identiﬁed HCM to
occur in at least 1 in 500 of the general population (0.2%)
(257,258). Nevertheless, it would appear that this
discrepancy is very likely attributable to the not insig-
niﬁcant false-negative diagnostic testing rate for HCM
using ECG, or history/physical examination. The Italian
data from Veneto reported new cases of HCM detected by
ECG and history/physical examination screening in 0.07%
of 33,735 athletes over a 17-year period (18).
Overall, themost commonly detected clinically reported
diseases reported in these studies were bicuspid aortic
valve, mitral valve prolapse, and Wolff-Parkinson-White
syndrome, with LQTS less common. Few studies have
described management strategies for those athletes with
detected abnormalities, and the reported disqualiﬁcation
rate is low (0.2%–4%) (66,225,254). No data are available
regarding the effect that such disqualiﬁcations have on
mortality rate.
COMMUNITY-BASED INITIATIVES WITH
NONINVASIVE TESTING IN THE UNITED STATES
For many years in the United States, cardiovascular
screening of young people aspiring to engage in
competitive sports has occurred in ofﬁce practices or in
relatively small populations such as individual colleges/
TABLE 2 Studies Examining Cardiovascular Screening of Trained Athletes*
Author/
Reference Year
No. of
Athletes
Age, Mean
(Range), y % Male Race, % Level Elite Country
% Abnormal
Sport
Other
Testing, % % DQ
Diseases
DetectedHx PE ECG Echo
Linder et al. (66) 1981 1,268 15 (12–19) N/A W: 65; B: 35 HS No U.S. 1.7 7.4 N/A N/A BB; FB 4.8 0.2 N/A
Maron et al. (88) 1987 501 19 (17–30) 71 W: 76; B: 23 C No U.S. 1.9 3.2 11.3 19 FB; T&F 20 0 1 HBP; 14 MVP;
3 >IVS
LaCorte et al. (253) 1989 1,424 13–18 N/A N/A HS No U.S. 6.5 N/A 5 0 N/A N/A 0 6 WPW
Lewis et al. (89) 1989 265 19 (18–28) 93 B: 99 C No U.S. N/A N/A N/A 24 FB; BB; T&F N/A N/A 1 ASD; 30 MVP;
4 HBP; 29 >IVS
Fuller et al. (254) 1997 5,615 13–19 60 N/A HS No U.S. 2 3.5 2.5 N/A N/A 10 0.4 1 AR; 5 HBP;
6 WPW; 1 SVT
Ma et al. (97) 2007 351 23 (13–33) 48 A: 100 N/A Yes China N/A N/A 4.5 4 N/A 0 0 3 >IVS; 13 MR
Stefani et al. (256) 2008 2,273 8–60 65 N/A N/A No Italy N/A 1.1 N/A 2.5 BB; S; T; Cy; SW N/A 0.7 58 BAV
Pelliccia et al.
(223)
2007 32,652 8–78 80 N/A N/A No Italy N/A N/A 12 (5% markedly
abnormal)
N/A BB; S; T; Cy; SW N/A N/A N/A
Basavarajaiah et al.
(96)
2008 3,500 13 (13–16) 75 N/A HS Yes UK N/A N/A N/A 4% S; T; RB; SW N/A N/A 6 WPW; 9 LQT
Magalski et al.
(225)
2008 1,959 23 (20–29) 100 W: 31; B: 67 Pro Yes U.S. N/A N/A 25 3 FB; R N/A 0 6 >IVS
Hevia et al. (104) 2011 1,220 23 96 N/A N/A No Spain 1 0.1 6 0.7 S 7.4 N/A 2 HCM
Baggish et al. (91) 2010 510 19 61 W: 68; B: 10;
A: 12
C No U.S. 3.8 2.3 17 2 N/A 6 0.6 1 PS; 1 HCM;
1 myocarditis
Malhotra et al.
(228)
2011 1,473 19 49 W: 71; B: 13;
A: 2
C No U.S. 6 6 19 N/A N/A 24 2 1 BAV; 4 WPW; 1 LQT;
1 CM; 5 EPS/ ablation
Magalski et al.
(227)
2011 964 N/A 48 W: 74
B: 20
A: 1
C No U.S. 23 3 35 (10% distinctly
abnormal)
1 FB; R; T&F N/A 0.9 1 LQT; 1 AOE; 7 WPW
Marek et al. (229) 2011 32,561 16 (14–19) N/A W: 66; B: 7;
A: 8
HS No U.S. N/A N/A 2.5 N/A N/A 2.5 N/A N/A
Rizzo et al. (255) 2012 3,100 11 (6–17) N/A N/A HS No Italy N/A N/A N/A 2 S N/A N/A 2 HCM; 23 BAV;
1 AOE; 10 MVP;
20 ASD
Thünenkötter et al.
(94)
2010 605 27 100 N/A Pro
(World Cup)
Yes Germany 1.5 3 4.8 1 S N/A 0 1 HCM
A indicates Asian; AOE, aortic enlargement; AR, aortic regurgitation; ASD, atrial septal defect; B, black; BAV, bicuspid aortic valve; BB, basketball; C, college; CM, cardiomyopathy; Cy, cycling; DQ, disqualiﬁed; Echo, echocardiography; EPS, electro-
physiological study; FB, football; HBP, high blood pressure; HCM, hypertrophic cardiomyopathy; HS, high school; Hx, history; >IVS, increased septal thickness; LQT, long-QT interval pattern; MR, mitral regurgitation; MVP, mitral valve prolapse; N/A, not
available; PE, physical examination; Pro, professional; PS, pulmonic stenosis; R, rowing; RB, rugby; S, soccer; SVT, supraventricular tachycardia; SW, swimming; T, tennis; T&F, track and ﬁeld; W, white; and WPW, Wolff-Parkinson-White syndrome. *Data
accessed as of May 2013.
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1499universities and high schools. Indeed, a number of
educational institutions have screened, or are currently
systematically screening, prospective athletes for heart
disease with a variety of research and nonresearch pro-
tocols that include echocardiograms or ECGs (259):
Harvard University, University of Wisconsin, Howard
University, University of Virginia, Georgetown University,
Stanford University, University of Washington, and other
institutions with programs in selected sports. Such
screening efforts have beneﬁted some young individuals
through identiﬁcation of potentially life-threatening car-
diovascular disorders. Such initiatives have been sup-
ported consistently by the 1996 and 2007 AHA Scientiﬁc
Statements (3,105), as well as the present document.
In addition, over the past decade, and stimulated by
the increasing recognition of SDs occurring in young
athletes, a multitude of public and community-based
preparticipation screening programs have emerged in the
United States for the purpose of identifying cardiovascu-
lar disease in athletes. These initiatives are often pro-
moted by fee-for-service vendors, and many advertise
solely on the Internet, with direct marketing to con-
sumers (i.e., parents, high schools, and athletic pro-
grams). Several such companies have started with great
enthusiasm and then ultimately dissolved after the
considerable logistical and technical challenges became
apparent (e.g., Heart Screen America [Massachusetts],
Ultrasound Services [Pennsylvania]); another fee-for-ser-
vice screening company in Illinois was closed by the
Attorney General when a technician was found to be
practicing medicine without a license by promoting
screening services to schools (Table 3). These real-world
programs also operate with a large measure of volun-
teerism and with funding derived from private nonproﬁt
foundations and government grants, fundraising dona-
tions, school budgets, for-proﬁt companies, hospitals,
medical schools, private practice physician groups, and
other sources often organized by parents of children with
SD. Notably, however, such initiatives are largely unreg-
ulated, independent, self-promoted medical enterprises,
and many have been short-lived, with very few outcome
data reported.
Community-based screening initiatives are conducted
in a variety of venues, including gymnasiums, community
centers, schools, and even houses of worship. Quality
control is a concern because of the variable expertise of
volunteer technicians and the inconsistent availability
and commitment of supervising physicians. In addition,
most of these programs operate without resources to
ensure follow-up after testing. The failure to obtain close
oversight from cardiovascular specialists can create a
situation in which the screening company is practicing
medicine without proper licensure, as well as the risk
that HIPAA (U.S. Health Insurance Portability andAccountability Act of 1996) privacy protection is not
ensured. Screening sessions are usually announced
through high schools, and attendance is voluntary, with
compliance highly dependent on the interest of the stu-
dents and their parents.
Some programs promote broad-based screening for
heart disease, whereas others have limited their scope to
HCM. Screening has been conducted with standard
2-dimensional echocardiography, although portable in-
struments (which may not incorporate recording capa-
bility) are commonly used, and sometimes with protocols
that by design limit scanning time. Typically, these pro-
grams underestimate those organizational and adminis-
trative tasks that extend beyond the performance of
echocardiograms or ECGs, including reliable parental
notiﬁcation of testing results; the securing of resources
necessary for enrollment, recruiting, and effective mar-
keting; and electronic data entry and storage. Also, some
subjects may choose not to seek second-tier evaluations
when recommended or may not have medical insurance
that permits access to cardiological consultation to
resolve diagnoses suspected by primary screening. There
is also potential liability when such screening programs
fail to diagnose lethal cardiac conditions and thereby
provide false assurance in the process.
There are currently several companies (e.g., Com-
puMed, Inc [California]; Prevention Health Network, LLC
[Kansas]; and Sportlink, advertised as “We heart you”)
and medical clinics (e.g., Saint Luke’s Athletic Heart
Clinic, Kansas City, MO) that market screening ECGs to
high schools, often citing sudden cardiac arrest risks and
aspiring to identify HCM or other diseases and prevent
SD. Many of these initiatives are limited to screening
ECGs, although others include echocardiograms. Some
programs partner with charitable organizations, and in-
dividual fees vary between $35 and $125. ECGs are sent
out for interpretation (sometimes overseas) or on con-
tract to area cardiologists. Now, after a decade,
numerous community screening efforts in trained ath-
letes have provided insights into the implementation
and feasibility of such programs and systems; however,
relatively little is known regarding the effectiveness of
disease detection or SD prevention, and few published
data have emerged.
PRACTICAL AND LOGISTICAL CONSIDERATIONS
There are multiple logistical and societal considerations
involved in evaluating a general population screening
protocol. Although proponents of mandatory screening
ECGs are well intentioned, several broad considerations
unavoidably impact these programs conceptually. First is
the ethical and fairness issue of conﬁning mass screening
ECGs to any one particular segment of society (e.g.,
TABLE 3 Community-Based Cardiovascular Screening Programs for Athletes and Nonathletes*
Organization
Year
Begun Subjects Location ECG Echo H & P
No.
Screened
to Date Funding Fee
Testing
Referral
Rate, %
Notiﬁcation
of Results†
Formal
DatabasePerform Interpret
Midwest Heart
Foundation
2006 HS Chicago, IL þ 0 0 51,000 Donations; grants;
industry;
school system
Free Trained
laypeople/medical
volunteers
Single volunteer
cardiologist
2 C þ
Anthony Bates
Foundation
2002 HS; college AZ; KS; CA þ þ 0 7,000 Industry;
fundraising;
donations
Donations
accepted
MPV Volunteer
cardiologists
10 A þ
Team of
Physicians for
Students
2000 HS Phoenix, AZ þ Selective;
limited
þ 18,000 Donations;
fundraising;
grants
Free Medical
professional/
student volunteers
Volunteer ER and
cardiologists
(on-site)
2–9 A þ
Chad
Foundation
2000 6 mo–30 y Los Angeles,
CA; NY
þ Limited þ 5,100 Donations;
fundraising;
grants
$25 MPV Volunteer
cardiologists
15–20 A 0
Heartfelt
Project
2007 5–24 y CA þ Limited þ 10,000 Foundation Donations
accepted
<$100
MPV Volunteer
cardiologists
(off-site)
1–2
(to cardiologists)
B 0
Heart for Sports 1999–2007
(now inactive)
HS CA; FL; NY;
MA; SC
0 þ þ 10,000 Donations;
grants
Free MPV Volunteer
cardiologists
(on-site)
1–2
(to cardiologists)
A 0
Championship
Hearts
Foundation
2000 HS Austin, TX 0 Limited 0/þ 11,200 Donations Free MPV Cardiologists
(on-site and
off-site)
N/A D þ
State of Texas 2008 HS TX þ Limited 0/þ 4,500 Grant: Texas
legislature
($1 million);
donations; grants
Free MPV Cardiologists
(on-site and
off-site)
8 D þ
Sparkling
Angels
2002 HS/junior
college
Orange
County, CA
þ 0 0 10,000 Donation;
fundraising
Free MPV 2 Cardiologists 3–5 B þ
Heart Hype 2008 HS (track
and ﬁeld)
Baltimore,
MD
þ Limited þ 900 Industry
donations
Free MPV Pediatric and adult
cardiologists
(on-site)
1 A þ
Stanford
University
2000 College Palo Alto,
CA
þ Selective;
limited
þ 4,000 Athletic
department;
funds; time
donated from
medical staff
Free Medical
professionals
(volunteer and
paid staff)
Medical
professionals
(on-site); off-site
cardiologists
N/A A þ
Beaumont
Hospital
2007 13–18 y Detroit,
MI area
þ Selective þ 8,000 Internal $25 MPV Cardiologists 10 D þ
Cypress ECG
Project
2009/2011 HS
(athletes)
TX/WA þ Referred 0 20,000 Fee for
service/501c3
$10–$15 Nonmedical
staff
Cardiologist
(off-site)
4 E þ
þ indicates present; 0, absent; AZ, Arizona; CA, California; Echo, echocardiography; ER, emergency room physicians; FL, Florida; H&P, history and physical examination; HS, high school; IL, Illinois; KS, Kansas; MA, Massachusetts; MD, Maryland; MI,
Michigan; MPV, medical professional volunteers; N/A, not available; NY, New York; SC, South Carolina; TX, Texas; and WA, Washington. *Data accessed as of May 2013; minimum of 5000 ECGs performed and reported. †For notiﬁcation of results, A
indicates on-site documentation provided to participant or parent; B, notiﬁcation mailed to parent/guardian; C, online system with pass key for participants to retrieve reports; and D, combination of A and B.
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1501competitive athletes, or college students who are ath-
letes), which can be regarded as narrow in scope and in
effect exclusionary (if not discriminatory and elitist), and
therefore ethically unjustiﬁable. For example, it would
not be sustainable to limit preparticipation screening to
male athletes just because SD rates are much lower in
female participants (1:9) (1,2,6,7,37,128), or to athletes in
sports such as basketball and football because those
sports are associated with higher risk than others.
In purely theoretical terms, fairness on this issue would
require national screening ECGs to be available to all
60 million individuals in the United States aged 12 to 25
years; however, that is obviously an impractical initiative
(if not virtually impossible logistically) that would
undoubtedly be encumbered by enormous numbers of
false-positive and false-negative results (231,241); and
consequently, it is not recommended by the present
writing group. A mandatory national and federally funded
initiative, whether it was conﬁned to athletes or was
extended to the general population, would undoubtedly
be confronted with signiﬁcant societal obstacles.
The argument advanced by some that a large, expen-
sive program for millions of citizens is justiﬁable as long
as it results in even a single life saved is an emotional
(albeit understandable) perspective that ignores a multi-
tude of scientiﬁc practical, ethical, and economic con-
siderations. Concerns about equity and fairness apply to
any screening program, i.e., in national or other large
populations, and to community, college/university, or
high school–based screening initiatives that traditionally
target athletes and essentially exclude other students
from access to the same testing capable of detecting
potentially lethal diseases, even when public funds or
resources are used.
Notably, there is no reason to believe that the largely
genetic heart diseases responsible for sudden and unex-
pected death in young people occur any more frequently
in athletes than nonathletes, and therefore, the absolute
number of such SDs must necessarily be higher in the
larger group of nonathletes. Indeed, by design, cardio-
vascular screening has been conﬁned to a highly selected
segment of the potential at-risk population. For example,
in the context of young students, only approximately one
third participate in organized high school competitive
sports, and just 1% are engaged in intercollegiate
athletics.
In addition, societal and cultural considerations may
create resistance and limit public acceptance of manda-
tory screening, including the inevitable perception by
some that disqualiﬁcation from sports and lost eligibility
represents an infringement on individual liberty and the
freedom to assume personal risks (even for SD). This may
explain the experience of several investigators, including
Marek et al. (229), who found that even when screeningECGs were offered at no cost to high school students in
the Chicago, IL, metropolitan area, only z50% of those
eligible ultimately elected to participate in the program.
Furthermore, the current debate concerning screening
ECGs is taking place at a time when the effectiveness and
also the prudence of mass screening tests for cancer
(i.e., breast [mammography] [260,261], prostate [prostate-
speciﬁc antigen test] [262–266], colorectal [colonoscopy]
[263–266], ovarian [266], and lung [266,267]) are being
questioned. Relevant to this discussion is the current
environment in which a substantial proportion of Ameri-
cans are opposed to mandates within the healthcare
system.
WORLD HEALTH ORGANIZATION CRITERIA
FOR MASS SCREENING
Designing the optimal and most practical strategy to
screen young people for underlying cardiovascular dis-
ease is complex, with a simple and deﬁnitive solution
seemingly elusive. The World Health Organization has
consistently advocated that such screening in asymp-
tomatic populations can be justiﬁed, provided that all
stipulated World Health Organization criteria are met
(268). However, it is apparent that the screening of large
general populations (or speciﬁcally athletes) for cardio-
vascular disease with ECGs does not appear to comply in
principle with such criteria for the following reasons:
n The 12-lead ECG does not qualify as a precise, vali-
dated, and suitable screening test known to reliably
distinguish the affected from the nonaffected.
n General agreement is lacking on the criteria for deﬁning
an abnormal ECG in screening such populations.
n Evidence is lacking from randomized or prospective
controlled trials showing that screening ECGs are
effective in reducing morbidity and mortality.
n Projected absolute costs of screening ECGs are not
balanced with respect to other medical care expendi-
tures in society.
n It is uncertain what proportion of the potential popu-
lation to be screened, when fully informed with regard
to the consequences of testing, would consent to
participate.
In other respects, however, mass screening ECGs are
consistent with World Health Organization principles
(263,268). For example, to be considered an important
public health problem, the diseases for which screening
is intended to detect are not required to be common
(which they are not, in the populations under consider-
ation here). Rather, the importance of a public health
problem is considered from the standpoint of both
the individual and the community. Thus, even rare
conditions with serious consequences to the individual
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1502and family may justify screening measures, as long
as detection will likely lead to effective treatment
interventions.SUMMARY OF PRIOR CONSENSUS
RECOMMENDATIONS CONCERNING
SCREENING ECGS IN POPULATIONS
1. AHA: Screening to detect cardiovascular disease in
athletes is supported in principle by the AHA. Accord-
ingly, a complete and targeted 12-point history and
physical examination performed by qualiﬁed exam-
iners was recommended in both 1996 and 2007
(3,105,112). The AHA does not support national
mandatory screening ECGs of athletes, because the
logistics, manpower, ﬁnancial, and resource consider-
ations make such a substantial program inapplicable to
the US healthcare system. Individual quality-
controlled local, community, or student-related ini-
tiatives were, however, supported by AHA if conducted
properly and with adequate resources.
2. The AHA recommended screening ECGs (as Class IIa)
for all children before administration of stimulant
medications used to treat attention deﬁcit/hyperac-
tivity disorders to avoid heart rhythm disturbances
that may occur with such drugs in children with
structural heart disease (269). An opposing viewpoint
was subsequently published by the American Academy
of Pediatrics (270).
3. ESC: The Sport Cardiology Study Group of the ESC
recommends systematic preparticipation screening for
young competitive athletes, including a family and
personal history, physical examination, and 12-lead
ECG (as in the Italian model) (5). This strategy has not
been translated on a national basis to other countries
(with the exception of Israel).
4. International Olympic Committee: The International
Olympic Committee recommends a targeted personal
and family history, physical examination, and 12-lead
ECG for all sports participants at the beginning of
competitive activity, and to be repeated every 2 years
thereafter (98,103,271). The commitment of national
Olympic teams to such programs throughout the world
is unclear, but to date this recommendation has not
been adopted in the United States.
5. A recent National Institutes of Health (National Heart,
Lung, and Blood Institute) position paper did not
support mass screening of young athletes (aged <40
years) with ECGs, concluding that insufﬁcient data
were currently available to resolve this controversy
(23). The working group recommended pilot screening
study ECGs in target populations to test the sensitivity
and speciﬁcity of the ECG for cardiac diagnosis but didnot offer funding or resources for such ambitious
projects.
ETHICAL CONSIDERATIONS
If one presumes a case could be made for the allocation of
resources for a mass screening program to detect poten-
tially life-threatening disorders of the heart in generally
healthy populations of young people, 3 key ethical chal-
lenges would need to be addressed to implement such
an initiative (272). First, who should give consent to
screening? Second, who will receive the results of
screening tests? And, third who will make a determina-
tion concerning what degree of risk is consistent with
participation in physical activities once test results are
obtained?
When children and adolescents are tested, it is almost
always an ethical requirement that parents or a guardian
be notiﬁed about the testing and that their consent be a
prerequisite for testing. Although there is some dispute
about whether both parents must give written consent for
minor children, generally parents have the right and
expect to be involved in the provision of any routine
medical diagnostic testing to their children, with the
possible exception of interventions pertaining to repro-
ductive and substance abuse matters (273).
Certain programs or states may approach parental
consent in a way similar to that which exists for many
vaccinations; that is, parental permission is presumed
prospectively, but there is an opportunity for a parent to
opt out of testing. On a presumption model of consent, a
child would automatically receive testing before partici-
pation in school-based or publicly sponsored sports ac-
tivities. The burden would fall on those sponsoring the
testing to inform parents of their right to opt their child
out of the testing program and then on parents to decide
whether to act on that decision.
The ability to opt out or decline can be made relatively
simple; for instance, parents can sign a standard form
brought to them by the student before testing, and the
student can return it to the testing location. Alternatively,
a declination form can be sent by the testing agent
directly to the parent before testing. Some commentators
have suggested that to discourage people from opting out,
the process can be made more difﬁcult by including re-
quirements for the parent or guardian to sign a declina-
tion of testing in person at the testing site, or in front of a
notary public, after receiving and understanding valid
information about the risk of sudden cardiac death in
young people from an appropriate healthcare provider
(274).
Children themselves have the right to assent to or
decline testing if they are mature enough to understand
the nature of the testing and the risks involved to their
J A C C V O L . 6 4 , N O . 1 4 , 2 0 1 4 Maron et al.
O C T O B E R 7 , 2 0 1 4 : 1 4 7 9 – 5 1 4 Assessment of the 12-Lead ECG as a Screening Test
1503privacy and ability to play sports. Many states recognize
that as children mature, they should become the guard-
ians of their own personal health information and part-
ners in medical decision-making, supplementing the
responsibility ordinarily held by their parents (274a). This
means that screening programs must have policies in
place to deal with refusals by mature children, requests
for testing by adolescents despite parental refusal, and
requests by children not to inform their parents of either
the testing or its results.
Test results should be disclosed to parents and to those
children old enough to understand them as allowed by
law. It is part of the informed consent process to disclose
the fact that other parties will have access to test results.
Physicians undertaking screening may do so as “gate-
keepers,” also controlling the right to allow participation
in certain sports or physical activities. But even if
authorized to control and limit participation, they may
also wish to share negative or concerning test results with
a child’s primary care provider or a specialist or other
third parties. There must be clear rules governing
disclosure of test results to anyone beyond the child and
parents or guardian. It is also important to design a policy
in advance that dictates how to process important infor-
mation that may be disclosed during testing (e.g., preg-
nancy, abuse, suicidal thoughts) that is not being sought
but nevertheless may be offered by the child.
Anyone not in direct care of the child cannot obtain
access to medical information about the child without the
express written consent of a parent (275). This includes
school authorities, coaches, team physicians, school
nurses, trainers, the media, or any other party not
providing direct clinical care (276). Diagnostic test results
concerning risk factors for SD will not sustain an argu-
ment for disclosure that overrides the presumption of
conﬁdentiality with respect to parents and their children.
Moreover, if disclosure results in adverse consequences
for the child in terms of social stigma, psychological harm,
or difﬁculty in ﬁnding insurance or employment or in any
other way, then liability may fall on anyone who discloses
test results to those not involved in the provision of
clinical care to the child.
Lastly, it should not be assumed that an abnormal test
result will always be accepted by either a child or parent
as a sufﬁcient basis for exclusion from a particular type of
activity. Although medical screening for diseases and
disorders such as epilepsy or infectious and communi-
cable diseases may be grounds for exclusion from certain
types of activities or settings, the determination of risk is
not the same as a diagnosis of disease. There may well be
disputes about how to best manage risk, particularly with
children who are skilled athletes or parents who wish to
zealously promote the athletic careers of their child.
Even in the face of catastrophic outcome, risk informationis not beyond challenge with respect to exclusionary
policies or requests for special accommodation. Although
not the opinion or expressed policy of the AHA, the
writing group believe that it may take legislation to
mandate exclusion from sports activity with an adverse
test result over parental or child objections.
MEDICAL-LEGAL CONSIDERATIONS
Mass screening of people 12 to 25 years of age (a popula-
tion of z60 million males and females in the United
States) for cardiovascular abnormalities is not legisla-
tively mandated by the U.S. Congress or any state legis-
lature. Even though a signiﬁcant percentage of this
population participates in compulsory physical education
classes or voluntary recreational or competitive athletics
involving strenuous exercise, which may increase the risk
of SD caused by a latent cardiovascular abnormality, no
major U.S. national medical organization or society has
recommended that a 12-lead ECG be required as part of
mass screening for cardiovascular abnormalities. More-
over, based on a thorough analysis of the relevant medical
and economic factors (as well as practical considerations),
the 1996 and 2007 AHA recommendations (3,105) devel-
oped by an experienced group of U.S. medical experts did
not recommend use of a 12-lead ECG as part of mass
screening for a subset of the population, that is,
competitive athletes (who number z10 million), despite
documented but rare instances of SD during athletic
competition, conditioning, or training.
The United States has not enacted any legislation
similar to the national laws of countries such as Italy
(4,18,116,244) and Israel (28,29,92,93,246), both of which
require use of a 12-lead ECG as part of mandatory pre-
participation screening to identify cardiovascular disease
in all people desiring to participate in organized
competitive athletics. The laws of these 2 countries, even
when combined with several European countries’ volun-
tary adoption of the International Olympic Committee
recommendation that an ECG be part of cardiovascular
screening for Olympic athletes, do not conclusively
establish an international standard or custom to require
use of a 12-lead ECG in mass screening of large pop-
ulations of young people for cardiovascular abnormal-
ities. Even if it were sufﬁcient to establish an
international (or European) standard, current law (which
is sparse) suggests that U.S. courts would apply a national
or state standard of care determined by the U.S. medical
profession in any litigation alleging that the failure to use
a 12-lead ECG as part of routine mass screening to detect
cardiovascular abnormalities constitutes medical
malpractice (276,277).
Medicine and the law have the same objectives
of ensuring that reliable, scientiﬁcally based, and
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screening of large general populations. U.S. law recog-
nizes that the medical profession is in the best position to
determine the appropriate nature and scope of recom-
mended screening for pathological abnormalities in any
large domestic population, including the attendant costs
and beneﬁts of the screening examination as a whole, as
well as each of its individual components (90,278,279).
U.S. law permits the U.S. medical profession to use the
best available scientiﬁc research and its members’ col-
lective medical judgment to develop consistent, reliable,
cost-effective guidelines and protocols to identify latent
genetic or congenital cardiovascular abnormalities within
certain segments of the population. Therefore, the pre-
sent 2014 AHA guidelines should be based on the best
available objective evidence and the underlying premise
that cardiovascular screening programs (independent of
size, scope, or design) should be driven by sound scien-
tiﬁc principles and policy rather than by relatively rare
catastrophic events, emotion, or subjective political
pressure from advocacy groups that is not medically or
scientiﬁcally based.
The law requires that individual physicians use
reasonable care when conducting medical examinations
for the purpose of detecting foreseeable medical abnor-
malities that may cause SD or serious injury (277). This
legal standard, which is established by the applicable
state tort law, historically requires a physician to follow
customary medical practice (i.e., what is usually done) in
his or her specialty. However, accepted (i.e., what is
appropriate to do) or reasonable conduct under the cir-
cumstances (i.e., what a reasonable physician would have
done) is now the standard of care in many states (280).
A physician is not per se legally liable for an athlete’s
injury or death caused by an undiscovered cardiovascular
condition or abnormality. Depending on the particular
jurisdiction, malpractice liability for failure to discover a
latent, asymptomatic cardiovascular disease requires
proof that the examining physician deviated from
customary, accepted, or reasonable medical practice in
his or her specialty while performing screening, and that
proper use of appropriate diagnostic criteria would likely
have disclosed the underlying medical condition before
injury or death occurred.
Even if some US cardiologists and other physicians
believe that use of a 12-lead ECG as a part of mass
screening of young athletes for cardiovascular abnormal-
ities constitutes “best practice,” and some educational
institutions use it in screening their student-athletes,
failing to do so does not necessarily constitute medical
malpractice.
Currently, there is no deﬁnitive judicial precedent (i.e.,
judge-made case law) concerning the legal effect of
compliance or noncompliance with the 1996 or 2007 AHAscreening recommendations in medical malpractice liti-
gation (90,279). Thus, it is important to understand that as
with those recommendations, the legal effect of the pre-
sent 2014 screening guidelines is uncertain and will likely
vary by jurisdiction. In some states, these guidelines may
constitute some evidence of the medical standard of care
for mass screening of large populations of young people.
In other states, compliance with these guidelines may
establish a rebuttable presumption that a physician has in
fact met the appropriate legal standard of care, or this may
not even be admissible evidence concerning the issue. In
most states, however, the legal consequences of failure to
comply with AHA screening guidelines cannot be deter-
mined deﬁnitively at this time (281).
Despite the lack of any speciﬁc legal precedent to
minimize potential legal liability for medical malpractice,
it is prudent for physicians to provide the minimum level
of screening recommended by the present AHA guidelines
(e.g., 14-point medical history and physical examination)
when conducting mass screening of large, generally
healthy populations of young people (281). Courts have
recognized that it is appropriate for physicians to follow
current consensus screening guidelines in determining an
athlete’s cardiovascular ﬁtness to participate in compet-
itive sports, thereby suggesting that this is evidence of
good medical practice (282,283). There is a strong argu-
ment that compliance with the minimum requirements of
the guidelines constitutes at least some evidence of
physician conformity to the medical standard of care
and may provide the basis for a successful defense
against alleged malpractice. On the other hand, failure to
provide the minimum level of screening recommended by
these guidelines may give rise to litigation that could
result in medical malpractice liability for death or injury
caused by a cardiovascular abnormality that probably
would have been discovered by following the guidelines
(278).
Although the present 2014 AHA guidelines do not
require testing with 12-lead ECGs as part of mass
screening for cardiovascular abnormalities, it is advisable
to inform young athletes and their parents of the poten-
tial beneﬁts and limitations of testing with 12-lead ECGs
in detecting cardiovascular disease, to answer their
questions, and to suggest they contact their personal
physician if its use as an additional screening tool in in-
dividual cases is desired.
Recommendations
The committee afﬁrms that cardiovascular screening
programs (independent of size, scope, or design) should
be driven by sound scientiﬁc principles and policy and
not by reaction to catastrophic events or political pres-
sure from advocacy groups. In light of this acknowledg-
ment and the data reviewed in the present document,
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screening in young people aged 12 to 25 years are
presented:
1. It is recommended that the AHA 14-point screening
guidelines (Table 1) and those of other societies,
such as the Preparticipation Physical Evaluation
monograph (115), be used by examiners as part of a
comprehensive history-taking and physical examina-
tion to detect or raise suspicion of genetic/congenital
and other cardiovascular abnormalities (Class I; Level
of Evidence C).
2. It is recommended that standardization of the ques-
tionnaire forms used as guides for examiners of high
school and college athletes in the United States be
pursued (Class I; Level of Evidence C).
3. Screening with 12-lead ECGs (or echocardiograms) in
association with comprehensive history-taking and
physical examination to identify or raise suspicion of
genetic/congenital and other cardiovascular abnor-
malities may be considered in relatively small co-
horts of young healthy people 12 to 25 years of age,
not necessarily limited to athletes (e.g., in high
schools, colleges/universities, or local communities),
provided that close physician involvement and suf-
ﬁcient quality control can be achieved. If under-
taken, such initiatives should recognize the known
and anticipated limitations of the 12-lead ECG
as a population screening test, including the ex-
pected frequency of false-positive and false-negative
test results, as well as the cost required to support
these initiatives over time (Class IIb; Level of Evi-
dence C).
4. Mandatory and universal mass screening with 12-lead
ECGs in large general populations of young healthy
people 12 to 25 years of age (including on a national
basis in the United States) to identify genetic/
congenital and other cardiovascular abnormalities is
not recommended for athletes and nonathletes alike
(Class III, no evidence of beneﬁt; Level of Evidence C).
5. Consideration for large-scale, general population, and
universal cardiovascular screening in the age group 12
to 25 years with history-taking and physical exami-
nation alone is not recommended (including on a na-
tional basis in the United States) (Class III, no
evidence of beneﬁt; Level of Evidence C).FINAL INSIGHTS
The preponderance of evidence indicates that SD in
young athletes (and probably nonathletes) in the age
range of 12 to 25 years should be regarded as a low event
rate occurrence. The writing group understands that
additional data regarding the cost efﬁcacy of screeninginitiatives and testing performance in large populations,
as well as the prevalence/incidence of SD events, would
be potentially helpful. However, to achieve a precise
incidence of SD in youthful populations would require a
national mandatory reporting process with a centralized
database and dedicated resources, a program that will be
difﬁcult to establish and maintain. Furthermore, a ran-
domized trial of sufﬁcient scale comparing mortality in
populations tested with ECGs versus populations not
tested with ECGs is impractical.
Therefore, currently, there is insufﬁcient information
available to support the view that universal screening
ECGs in asymptomatic young people for cardiovascular
disease is appropriate or possible on a national basis for
the United States, in competitive athletes or in the general
youthful population. The future evolution of mass
screening programs with ECGs in other countries ulti-
mately depends on the particular socioeconomic and
cultural background and available resources within these
particular healthcare systems.
At present, there is no mechanism available in the
United States to effectively create national programs of
such magnitude, whether limited to athletes or including
the wider population of all young people. Further-
more, there is insufﬁcient evidence that particularly
large-scale/mass screening initiatives are feasible or cost-
effective within the current U.S. healthcare infrastruc-
ture, or that routine 12-lead ECGs (supplemental to
history and physical examination) provide added mor-
tality beneﬁt for prevention of sudden cardiovascular
death. The ECG can promote detection of speciﬁc car-
diovascular diseases and thereby beneﬁt some in-
dividuals in a screening environment, but cannot be
regarded as an ideal or effective test when applied to
large healthy populations.
An additional, but unresolved, ethical issue concerns
whether students who voluntarily engage in competitive
athletic programs should have the advantage of cardio-
vascular screening, while others who choose not to be
involved in such activities (but may be at the same or
similar risk), are in effect excluded from the same op-
portunity. Therefore, in principal, it is prudent that
screening of relatively small populations of students
should not be restricted to competitive athletes, but
strong consideration should be given to making this pro-
cess available to all students.
The writing group acknowledges the tragic nature of
SDs in the young, but does not believe the available data
support a signiﬁcant public health beneﬁt from using the
12-lead ECG as a universal screening tool. The writing
group, however, does endorse more widespread dissem-
ination of automated external deﬁbrillators, which are
effective in saving young lives on the athletic ﬁeld and
elsewhere (125).
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